<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S2214109X21002990</prism:url><dc:identifier>doi:10.1016/S2214-109X(21)00299-0</dc:identifier><eid>1-s2.0-S2214109X21002990</eid><prism:doi>10.1016/S2214-109X(21)00299-0</prism:doi><pii>S2214-109X(21)00299-0</pii><dc:title>Economic impact of tuberculosis mortality in 120 countries and the cost of not achieving the Sustainable Development Goals tuberculosis targets: a full-income analysis </dc:title><prism:publicationName>The Lancet Global Health</prism:publicationName><prism:aggregationType>Journal</prism:aggregationType><pubType>fla</pubType><prism:issn>2214109X</prism:issn><prism:volume>9</prism:volume><prism:issueIdentifier>10</prism:issueIdentifier><prism:startingPage>e1372</prism:startingPage><prism:endingPage>e1379</prism:endingPage><prism:pageRange>e1372-e1379</prism:pageRange><prism:number>10</prism:number><dc:format>text/xml</dc:format><prism:coverDate>2021-10-31</prism:coverDate><prism:coverDisplayDate>October 2021</prism:coverDisplayDate><prism:copyright>© 2021 The Author(s). Published by Elsevier Ltd.</prism:copyright><prism:publisher>The Author(s). Published by Elsevier Ltd.</prism:publisher><dc:creator>Silva, Sachin</dc:creator><dc:creator>Arinaminpathy, Nimalan</dc:creator><dc:creator>Atun, Rifat</dc:creator><dc:creator>Goosby, Eric</dc:creator><dc:creator>Reid, Michael</dc:creator><dc:description>
                  Background
                  The tuberculosis targets for the UN Sustainable Development Goals (SDGs) call for a 90% reduction in tuberculosis deaths by 2030, compared with 2015, but meeting this target now seems highly improbable. To assess the economic impact of not meeting the target until 2045, we estimated full-income losses in 120 countries, including those due to excess deaths resulting from COVID-19-related disruptions to tuberculosis services, for the period 2020–50.
               
                  Methods
                  Annual mortality risk changes at each age in each year from 2020 to 2050 were estimated for 120 countries. This risk change was then converted to full-income risk by calculating a population-level mortality risk change and multiplying it by the value of a statistical life-year in each country and year. As a comparator, we assumed that current rates of tuberculosis continue to decline through the period of analysis. We calculated the full-income losses, and mean life expectancy losses per person, at birth and at age 35 years, under scenarios in which the SDG targets are met in 2030 and in 2045. We defined the cost of inaction as the difference in full-income losses and tuberculosis mortality between these two scenarios.
               
                  Findings
                  From 2020 to 2050, based on the current annual decrease in tuberculosis deaths of 2%, 31·8 million tuberculosis deaths (95% uncertainty interval 25·2 million–39·5 million) are estimated to occur, corresponding to an economic loss of US$17·5 trillion (14·9 trillion–20·4 trillion). If the SDG tuberculosis mortality target is met in 2030, 23·8 million tuberculosis deaths (18·9 million–29·5 million) and $13·1 trillion (11·2 trillion–15·3 trillion) in economic losses can be avoided. If the target is met in 2045, 18·1 million tuberculosis deaths (14·3 million–22·4 million) and $10·2 trillion (8·7 trillion–11·8 trillion) can be avoided. The cost of inaction of not meeting the SDG tuberculosis mortality target until 2045 (vs 2030) is, therefore, 5·7 million tuberculosis deaths (5·1 million–8·1 million) and $3·0 trillion (2·5 trillion–3·5 trillion) in economic losses. COVID-19-related disruptions add $290·3 billion (260·2 billion–570·1 billion) to this cost.
               
                  Interpretation
                  Failure to achieve the SDG tuberculosis mortality target by 2030 will lead to profound economic and health losses. The effects of delay will be greatest in sub-Saharan Africa. Affected countries, donor nations, and the private sector should redouble efforts to finance tuberculosis programmes and research because the economic dividend of such strategies is likely to be substantial.
               
                  Funding
                  None.
               </dc:description><openaccess>1</openaccess><openaccessArticle>true</openaccessArticle><openaccessType>Full</openaccessType><openArchiveArticle>false</openArchiveArticle><openaccessSponsorName>University of California (UC) 2021: Core Gold Lancet</openaccessSponsorName><openaccessSponsorType>FundingBody</openaccessSponsorType><openaccessUserLicense>http://creativecommons.org/licenses/by/4.0/</openaccessUserLicense><link href="https://api.elsevier.com/content/article/pii/S2214109X21002990" rel="self"/><link href="https://www.sciencedirect.com/science/article/pii/S2214109X21002990" rel="scidir"/></coredata><objects><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="643" height="1242" size="79892">https://api.elsevier.com/content/object/eid/1-s2.0-S2214109X21002990-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="643" height="417" size="35683">https://api.elsevier.com/content/object/eid/1-s2.0-S2214109X21002990-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="85" height="164" size="2602">https://api.elsevier.com/content/object/eid/1-s2.0-S2214109X21002990-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="142" size="5046">https://api.elsevier.com/content/object/eid/1-s2.0-S2214109X21002990-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2849" height="5501" size="618996">https://api.elsevier.com/content/object/eid/1-s2.0-S2214109X21002990-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2849" height="1848" size="263196">https://api.elsevier.com/content/object/eid/1-s2.0-S2214109X21002990-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="mmc1" category="standard" type="APPLICATION" multimediatype="Acrobat PDF file" mimetype="application/pdf" size="1974107">https://api.elsevier.com/content/object/eid/1-s2.0-S2214109X21002990-mmc1.pdf?httpAccept=%2A%2F%2A</object><object ref="si1" category="thumbnail" type="ALTIMG" multimediatype="GIF image file" mimetype="image/gif" width="296" height="44" size="1991">https://api.elsevier.com/content/object/eid/1-s2.0-S2214109X21002990-si1.gif?httpAccept=%2A%2F%2A</object><object ref="am" category="standard" type="AAM-PDF" multimediatype="Acrobat PDF file" mimetype="application/pdf" size="581530">https://api.elsevier.com/content/object/eid/1-s2.0-S2214109X21002990-am.pdf?httpAccept=%2A%2F%2A</object></objects><scopus-id>85114805864</scopus-id><scopus-eid>2-s2.0-85114805864</scopus-eid><pubmed-id>34487685</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/85114805864" rel="abstract"/><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>286970</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291904</xocs:ssid>
         <xocs:ssid type="subj">291910</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
         <xocs:ssid type="oa">90</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>The Lancet Global Health</xocs:srctitle>
      <xocs:normalized-srctitle>LANCETGLOBALHEALTH</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20210903">2021-09-03</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20210903">2021-09-03</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20210914">2021-09-14</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20210914">2021-09-14</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2023-05-25T12:54:56</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S2214109X21002990</xocs:eid>
      <xocs:pii-formatted>S2214-109X(21)00299-0</xocs:pii-formatted>
      <xocs:pii-unformatted>S2214109X21002990</xocs:pii-unformatted>
      <xocs:doi>10.1016/S2214-109X(21)00299-0</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.3</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S2214109X21X00113</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20230525">2023-05-25T12:03:07.934861Z</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20211001</xocs:date-search-begin>
      <xocs:date-search-end>20211031</xocs:date-search-end>
      <xocs:year-nav>2021</xocs:year-nav>
      <xocs:indexeddate epoch="1630711692">2021-09-03T23:28:12.45073Z</xocs:indexeddate>
      <xocs:articleinfo>articleinfo articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid fundingbodyid hubeid indexeddate issfirst issn issnnorm issuelist itemstage itemtransactionid itemweight oauserlicense openaccess openarchive pg pgfirst pglast pii piinorm pubdateend pubdatestart pubdatetxt pubyr sortorder sponsoredaccesstype srctitle srctitlenorm srctype ssids alllist content oa subj subheadings tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table e-component body mmlmath affil appendices articletitle auth authfirstini authfull authlast doctopic primabst pubtype ref</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>2214-109X</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>2214109X</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:sponsored-access-type>UNLIMITED</xocs:sponsored-access-type>
      <xocs:funding-body-id>CDLOALN21</xocs:funding-body-id>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>9</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>9</xocs:volume>
      </xocs:volume-list>
      <xocs:iss-first>10</xocs:iss-first>
      <xocs:issue-list>
         <xocs:issue>10</xocs:issue>
      </xocs:issue-list>
      <xocs:vol-iss-suppl-text>Volume 9, Issue 10</xocs:vol-iss-suppl-text>
      <xocs:sort-order>24</xocs:sort-order>
      <xocs:first-fp>e1372</xocs:first-fp>
      <xocs:last-lp>e1379</xocs:last-lp>
      <xocs:pages>
         <xocs:first-page>e1372</xocs:first-page>
         <xocs:last-page>e1379</xocs:last-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>202110</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>October 2021</xocs:cover-date-text>
      <xocs:cover-date-start>2021-10-01</xocs:cover-date-start>
      <xocs:cover-date-end>2021-10-31</xocs:cover-date-end>
      <xocs:cover-date-year>2021</xocs:cover-date-year>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>fla</xocs:document-subtype>
      <xocs:copyright-line>© 2021 The Author(s). Published by Elsevier Ltd.</xocs:copyright-line>
      <xocs:normalized-article-title>ECONOMICIMPACTTUBERCULOSISMORTALITYIN120COUNTRIESCOSTNOTACHIEVINGSUSTAINABLEDEVELOPMENTGOALSTUBERCULOSISTARGETSAFULLINCOMEANALYSIS</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>SILVA</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>S</xocs:normalized-first-auth-initial>
      <xocs:refers-to>
         <xocs:refers-to-doi>10.1016/S2214-109X(21)00345-4</xocs:refers-to-doi>
         <xocs:refers-to-pii-unformatted>S2214109X21003454</xocs:refers-to-pii-unformatted>
      </xocs:refers-to>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Methods</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Study design</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Procedures</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Role of the funding source</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Results</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Discussion</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Data sharing</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:appendices">
            <xocs:item-toc-section-title>Supplementary Material</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sbref10">
            <xocs:ref-normalized-surname>REID</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1331</xocs:ref-first-fp>
            <xocs:ref-last-lp>1384</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref20">
            <xocs:ref-normalized-surname>FLOYD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>723</xocs:ref-first-fp>
            <xocs:ref-last-lp>730</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref30">
            <xocs:ref-normalized-surname>MENZIES</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>e816</xocs:ref-first-fp>
            <xocs:ref-last-lp>e826</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref40">
            <xocs:ref-normalized-surname>HOGAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>e1132</xocs:ref-first-fp>
            <xocs:ref-last-lp>e1141</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref50">
            <xocs:ref-normalized-surname>BUONSENSO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2021</xocs:ref-pub-year>
            <xocs:ref-first-fp>67</xocs:ref-first-fp>
            <xocs:ref-last-lp>69</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref60">
            <xocs:ref-normalized-surname>VENKATESAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>e64</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref70">
            <xocs:ref-normalized-surname>CILLONI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-article-number>100603</xocs:ref-article-number>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref80">
            <xocs:ref-normalized-surname>REID</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>1312</xocs:ref-first-fp>
            <xocs:ref-last-lp>1313</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref90"/>
         <xocs:ref-info refid="sbref100"/>
         <xocs:ref-info refid="sbref110">
            <xocs:ref-normalized-surname>LAXMINARAYAN</xocs:ref-normalized-surname>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref120">
            <xocs:ref-normalized-surname>VASSALL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>255</xocs:ref-first-fp>
            <xocs:ref-last-lp>265</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
            <xocs:ref-normalized-srctitle>PRIORITIZINGDEVELOPMENTACOSTBENEFITANALYSISUNITEDNATIONSSUSTAINABLEDEVELOPMENTGOALS</xocs:ref-normalized-srctitle>
            <xocs:ref-normalized-article-title>BENEFITSCOSTSTBCONTROLFORPOST2015DEVELOPMENTAGENDA</xocs:ref-normalized-article-title>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref130">
            <xocs:ref-normalized-surname>RAJESWARI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>869</xocs:ref-first-fp>
            <xocs:ref-last-lp>877</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref140">
            <xocs:ref-normalized-surname>SU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>929</xocs:ref-first-fp>
            <xocs:ref-last-lp>942</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref150">
            <xocs:ref-normalized-surname>PAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>1575</xocs:ref-first-fp>
            <xocs:ref-last-lp>1580</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref160">
            <xocs:ref-normalized-surname>LONNROTH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-article-number>e1001693</xocs:ref-article-number>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref170">
            <xocs:ref-normalized-surname>BLOOM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>233</xocs:ref-first-fp>
            <xocs:ref-last-lp>314</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
            <xocs:ref-normalized-srctitle>MAJORINFECTIOUSDISEASES</xocs:ref-normalized-srctitle>
            <xocs:ref-normalized-article-title>TUBERCULOSIS</xocs:ref-normalized-article-title>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref180">
            <xocs:ref-normalized-surname>DELFINO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>719</xocs:ref-first-fp>
            <xocs:ref-last-lp>743</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref190">
            <xocs:ref-normalized-surname>NORDHAUS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref200">
            <xocs:ref-normalized-surname>JAMISON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>1898</xocs:ref-first-fp>
            <xocs:ref-last-lp>1955</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref210">
            <xocs:ref-normalized-surname>UPLEKAR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>1799</xocs:ref-first-fp>
            <xocs:ref-last-lp>1801</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref220">
            <xocs:ref-normalized-surname>PRESTON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
            <xocs:ref-normalized-srctitle>DEMOGRAPHYMEASURINGMODELINGPOPULATIONPROCESSES</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref230"/>
         <xocs:ref-info refid="sbref240"/>
         <xocs:ref-info refid="sbref250">
            <xocs:ref-normalized-surname>GLAZIOU</xocs:ref-normalized-surname>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref260"/>
         <xocs:ref-info refid="sbref270"/>
         <xocs:ref-info refid="sbref280"/>
         <xocs:ref-info refid="sbref290">
            <xocs:ref-normalized-surname>ROBINSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>14</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref300">
            <xocs:ref-normalized-surname>TANTORRESEDEJER</xocs:ref-normalized-surname>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref310">
            <xocs:ref-normalized-surname>ORWA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>73</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref320">
            <xocs:ref-normalized-surname>ROBINSON</xocs:ref-normalized-surname>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref330"/>
         <xocs:ref-info refid="sbref340">
            <xocs:ref-normalized-surname>BLOOM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
            <xocs:ref-normalized-srctitle>DEMOGRAPHICDIVIDENDANEWPERSPECTIVEECONOMICCONSEQUENCESPOPULATIONCHANGE</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref350">
            <xocs:ref-normalized-surname>BLOOM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>63</xocs:ref-first-fp>
            <xocs:ref-last-lp>76</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref360">
            <xocs:ref-normalized-surname>ROMANOWSKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1129</xocs:ref-first-fp>
            <xocs:ref-last-lp>1137</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref370">
            <xocs:ref-normalized-surname>FUADY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>3</xocs:ref-first-fp>
            <xocs:ref-last-lp>10</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref380">
            <xocs:ref-normalized-surname>MUNIYANDI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-article-number>e1920973</xocs:ref-article-number>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref390">
            <xocs:ref-normalized-surname>MANDAL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>47</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref400">
            <xocs:ref-normalized-surname>SWAMINATHAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>855</xocs:ref-first-fp>
            <xocs:ref-last-lp>870</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref410">
            <xocs:ref-normalized-surname>HAMMITT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>29</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref420">
            <xocs:ref-normalized-surname>FLEURBAEY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>711</xocs:ref-first-fp>
            <xocs:ref-last-lp>729</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref430">
            <xocs:ref-normalized-surname>PATENAUDE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>151</xocs:ref-first-fp>
            <xocs:ref-last-lp>156</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>SILVAX2021Xe1372</xocs:refkey3>
         <xocs:refkey4lp>SILVAX2021Xe1372Xe1379</xocs:refkey4lp>
         <xocs:refkey4ai>SILVAX2021Xe1372XS</xocs:refkey4ai>
         <xocs:refkey5>SILVAX2021Xe1372Xe1379XS</xocs:refkey5>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="1" is-open-archive="0">Full</xocs:oa-article-status>
         <xocs:oa-access-effective-date>2021-06-21T13:05:45Z</xocs:oa-access-effective-date>
         <xocs:oa-sponsor>
            <xocs:oa-sponsor-type>FundingBody</xocs:oa-sponsor-type>
            <xocs:oa-sponsor-name>University of California (UC) 2021: Core Gold Lancet</xocs:oa-sponsor-name>
         </xocs:oa-sponsor>
         <xocs:oa-user-license>http://creativecommons.org/licenses/by/4.0/</xocs:oa-user-license>
      </xocs:open-access>
      <xocs:copyright-info>
         <xocs:cp-license-lines>
            <xocs:cp-license-line lang="en">This is an open access article under the CC BY license.</xocs:cp-license-line>
         </xocs:cp-license-lines>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">© 2021 The Author(s). Published by Elsevier Ltd.</xocs:cp-notice>
         </xocs:cp-notices>
      </xocs:copyright-info>
      <xocs:article-sharing-framework/>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S2214-109X(21)00299-0</xocs:pii-formatted>
         <xocs:pii-unformatted>S2214109X21002990</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S2214109X21002990</xocs:eid>
         <xocs:doi>10.1016/S2214-109X(21)00299-0</xocs:doi>
         <xocs:cid>286970</xocs:cid>
         <xocs:timestamp>2023-05-25T12:03:07.934861Z</xocs:timestamp>
         <xocs:cover-date-start>2021-10-01</xocs:cover-date-start>
         <xocs:cover-date-end>2021-10-31</xocs:cover-date-end>
         <xocs:sponsored-access-type>UNLIMITED</xocs:sponsored-access-type>
         <xocs:funding-body-id>CDLOALN21</xocs:funding-body-id>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S2214109X21002990-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S2214109X21002990/MAIN/application/pdf/337e804fc63daf1b9dc70ff8ef8d2146/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>449720</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>8</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S2214109X21002990-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S2214109X21002990/PREVIEW/image/png/1ed58a5b196122fa2453bd124b358664/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>92014</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S2214109X21002990-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S2214109X21002990/gr1/DOWNSAMPLED/image/jpeg/91b1db85aafff4dff6321708ee7a81ec/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>79892</xocs:filesize>
               <xocs:pixel-height>1242</xocs:pixel-height>
               <xocs:pixel-width>643</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S2214109X21002990-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S2214109X21002990/gr2/DOWNSAMPLED/image/jpeg/4de950e1e23e3cea57089047e8637961/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>35683</xocs:filesize>
               <xocs:pixel-height>417</xocs:pixel-height>
               <xocs:pixel-width>643</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S2214109X21002990-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S2214109X21002990/gr1/THUMBNAIL/image/gif/c7f8ded003fa222b8fb0831820649917/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2602</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>85</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S2214109X21002990-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S2214109X21002990/gr2/THUMBNAIL/image/gif/df32050d120f911d9388f321b16fd70c/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5046</xocs:filesize>
               <xocs:pixel-height>142</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S2214109X21002990-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S2214109X21002990/HIGHRES/image/jpeg/9485665e7466a979d4b27dfb336f5270/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>618996</xocs:filesize>
               <xocs:pixel-height>5501</xocs:pixel-height>
               <xocs:pixel-width>2849</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S2214109X21002990-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S2214109X21002990/HIGHRES/image/jpeg/07b2144ca8bae2b3decf7c5c64ea5041/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>263196</xocs:filesize>
               <xocs:pixel-height>1848</xocs:pixel-height>
               <xocs:pixel-width>2849</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S2214109X21002990-mmc1.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S2214109X21002990/mmc1/MAIN/application/pdf/d5a9b9f1dd18c23f8adc7dddc1542812/mmc1.pdf</xocs:ucs-locator>
               <xocs:file-basename>mmc1</xocs:file-basename>
               <xocs:filename>mmc1.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>false</xocs:pdf-optimized>
               <xocs:filesize>1974107</xocs:filesize>
               <xocs:attachment-type>APPLICATION</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S2214109X21002990-si1.gif</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S2214109X21002990/STRIPIN/image/gif/7f0c74f103f882c183c3a178682e143a/si1.gif</xocs:ucs-locator>
               <xocs:file-basename>si1</xocs:file-basename>
               <xocs:filename>si1.gif</xocs:filename>
               <xocs:extension>gif</xocs:extension>
               <xocs:filesize>1991</xocs:filesize>
               <xocs:pixel-height>44</xocs:pixel-height>
               <xocs:pixel-width>296</xocs:pixel-width>
               <xocs:attachment-type>ALTIMG</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S2214109X21002990-am.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/egi:10292VXM1C9/MAIN/application/pdf/21d22774c4f2ce271a46b401cdc70bab/am.pdf</xocs:ucs-locator>
               <xocs:file-basename>am</xocs:file-basename>
               <xocs:filename>am.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>false</xocs:pdf-optimized>
               <xocs:filesize>581530</xocs:filesize>
               <xocs:attachment-type>AAM-PDF</xocs:attachment-type>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" docsubtype="fla" version="5.6" xml:lang="en">
         <item-info>
            <jid>LANGLO</jid>
            <aid>2112</aid>
            <ce:pii>S2214-109X(21)00299-0</ce:pii>
            <ce:doi>10.1016/S2214-109X(21)00299-0</ce:doi>
            <ce:document-thread>
               <ce:refers-to-document id="cereftodoc10">
                  <ce:pii>S2214-109X(21)00345-4</ce:pii>
                  <ce:doi>10.1016/S2214-109X(21)00345-4</ce:doi>
               </ce:refers-to-document>
            </ce:document-thread>
            <ce:copyright type="other" year="2021">The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license</ce:copyright>
            <ce:doctopics>
               <ce:doctopic id="cedoct10">
                  <ce:text>Primary Research</ce:text>
               </ce:doctopic>
               <ce:doctopic id="cedoct20">
                  <ce:text>Articles</ce:text>
               </ce:doctopic>
            </ce:doctopics>
         </item-info>
         <ce:floats>
            <ce:figure id="fig1">
               <ce:label>Figure 1</ce:label>
               <ce:caption id="cecap10">
                  <ce:simple-para id="spara10" role="caption" view="all">Economic losses by World Bank region in 2020–50 under three scenarios for reductions in tuberculosis mortality</ce:simple-para>
                  <ce:simple-para id="spara20" role="key" view="all">(A) Business-as-usual scenario. (B) Tuberculosis mortality target met in 2030. (C) Tuberculosis mortality target met in 2045. Error bars represent 95% uncertainty intervals.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr1" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S2214109X21002990/gr1"/>
            </ce:figure>
            <ce:figure id="fig2">
               <ce:label>Figure 2</ce:label>
               <ce:caption id="cecap20">
                  <ce:simple-para id="spara30" role="caption" view="all">The cost of inaction by World Bank region</ce:simple-para>
                  <ce:simple-para id="spara40" role="key" view="all">Costs represent the full-income savings from meeting the tuberculosis mortality targets in 2030 rather than in 2045. Error bars represent 95% CIs.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr2" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S2214109X21002990/gr2"/>
            </ce:figure>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl1" frame="topbot" rowsep="0" colsep="0">
               <ce:label>Table 1</ce:label>
               <ce:caption id="cecap30">
                  <ce:simple-para id="spara50" role="caption" view="all">Mean life expectancy loss per person in 2030, at birth and at age 35 years</ce:simple-para>
               </ce:caption>
               <tgroup cols="9">
                  <colspec colnum="1" colname="col1"/>
                  <colspec colnum="2" colname="col2"/>
                  <colspec colnum="3" colname="col3"/>
                  <colspec colnum="4" colname="col4"/>
                  <colspec colnum="5" colname="col5"/>
                  <colspec colnum="6" colname="col6"/>
                  <colspec colnum="7" colname="col7"/>
                  <colspec colnum="8" colname="col8"/>
                  <colspec colnum="9" colname="col9"/>
                  <thead>
                     <row valign="top" rowsep="1">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>East Asia and Pacific</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Europe and central Asia</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Latin America and Caribbean</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Middle East and north Africa</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>North America</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>South Asia</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Sub-Saharan Africa</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Global average</bold>
                        </entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" namest="col1" nameend="col9">
                           <bold>Life expectancy at birth</bold>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Business-as-usual scenario</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·27 (0·77)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·04 (0·14)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·08 (0·19)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·05 (0·15)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·01 (0·03)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·39 (0·86)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·84 (1·23)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·31 (0·49)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Target met in 2030</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·04 (0·46)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·01 (0·09)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·01 (0·15)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·01 (0·08)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·00 (0·04)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·06 (0·63)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·13 (1·38)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·05 (0·08)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Savings from meeting target in 2030</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·22</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·04</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·07</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·04</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·00</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·33</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·72</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·26</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Target met in 2045</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·13 (1·37)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·02 (0·24)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·04 (0·39)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·02 (0·24)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·00 (0·05)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·18 (1·99)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·40 (4·40)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·15 (0·24)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Savings from meeting target in 2045</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·14</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·02</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·04</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·02</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·00</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·21</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·44</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·16</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Cost of inaction</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·08</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·01</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·02</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·01</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·00</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·28</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·10</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" namest="col1" nameend="col9">
                           <bold>Life expectancy at age 35 years</bold>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Business-as-usual scenario</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·12 (1·36)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·02 (0·22)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·05 (0·51)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·02 (0·24)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·00 (0·03)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·18 (1·97)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·46 (5·05)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·17 (0·26)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Target met in 2030</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·02 (0·20)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·00 (0·04)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·01 (0·07)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·00 (0·03)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·00 (0·00)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·03 (0·29)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·07 (0·75)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·02 (004)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Savings from meeting target in 2030</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·11</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·02</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·04</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·02</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·00</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·39</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·14</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Target met in 2045</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·06 (0·62)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·01 (0·11)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·02 (0·22)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·01 (0·11)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·00 (0·01)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·08 (0·93)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·22 (2·39)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·08 (0·13)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Savings from meeting target in 2045</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·07</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·01</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·03</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·01</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·00</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·09</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·24</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·09</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Cost of inaction</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·04</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·01</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·01</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·01</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·00</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·06</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0·05</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:legend>
                  <ce:simple-para id="spara60" view="all">Data are presented as mean life expectancy loss (SD), in years, by World Bank region. Life expectancy at birth represents the average number of years that a newborn could expect to live, if he or she were subject to the age-specific mortality rates of a given period. Life expectancy at age 35 years represents the average number of years that an individual at exact age 35 years is expected to live, if he or she were subject to the age-specific mortality rates of a given period. All estimates include people living with HIV.</ce:simple-para>
               </ce:legend>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl2" frame="topbot" rowsep="0" colsep="0">
               <ce:label>Table 2</ce:label>
               <ce:caption id="cecap40">
                  <ce:simple-para id="spara70" role="caption" view="all">The cost of inaction in terms of tuberculosis deaths and economic losses, by World Bank region, from 2020 to 2050</ce:simple-para>
               </ce:caption>
               <tgroup cols="10">
                  <colspec colnum="1" colname="col1"/>
                  <colspec colnum="2" colname="col2"/>
                  <colspec colnum="3" colname="col3"/>
                  <colspec colnum="4" colname="col4"/>
                  <colspec colnum="5" colname="col5"/>
                  <colspec colnum="6" colname="col6"/>
                  <colspec colnum="7" colname="col7"/>
                  <colspec colnum="8" colname="col8"/>
                  <colspec colnum="9" colname="col9"/>
                  <colspec colnum="10" colname="col10"/>
                  <thead>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" namest="col2" nameend="col8" rowsep="1">
                           <bold>Economic losses, 2018 $US billions</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Total economic losses, 2018 $US billions</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Total tuberculosis deaths, millions</bold>
                        </entry>
                     </row>
                     <row valign="top" rowsep="1">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">East Asia and Pacific</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Europe and central Asia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Latin America and Caribbean</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Middle East and north Africa</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">North America</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">South Asia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Sub-Saharan Africa</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Business-as-usual scenario</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5110 (4530–5750)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">763 (706–871)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">351 (303–402)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">172 (126–223)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">100 (96–103)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">7120 (6470–7850)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3840 (2690–5190)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">17 456 (14 921–20 389)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">31·8 (25·2–39·5)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Target met in 2030</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1250 (1110–1400)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">253 (239–268)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">93 (82–104)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">43 (32–57)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">48 (47–49)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1540 (1400–1690)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1110 (779–1510)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4337 (3689–5077)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">8·0 (6·3–10·1)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Savings from meeting target in 2030</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3860 (3420–4350)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">510 (467–603)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">258 (220–298)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">129 (94–166)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">52 (49–54)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5580 (5070–6160)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2730 (1911–3680)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">13 119 (11 232–15 311)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">23·8 (18·9–29·5)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Target met in 2045</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2080 (1840–2340)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">422 (396–450)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">162 (143–183)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">76 (57–101)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">58 (57–59)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2600 (2370–2860)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1900 (1330–2590)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">7299 (6192–8583)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">13·7 (10·8–17·2)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Savings from meeting target in 2045</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3030 (2690–3410)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">341 (310–421)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">189 (160–219)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">96 (69–122)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">42 (40–44)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4520 (4100–4990)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1940 (1360–2600)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10 157 (8729–11 805)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">18·1 (14·3–22·4)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Cost of inaction</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">830 (730–940)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">169 (157–182)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">69 (61–79)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">34 (25–44)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10 (10–11)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1060 (970–1170)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">790 (551–1080)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2962 (2503–3506)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5·7 (5·1–8·1)</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:legend>
                  <ce:simple-para id="spara80" view="all">The cost of inaction was computed as the difference in tuberculosis deaths and economic losses between the scenario of meeting the tuberculosis mortality target in 2030 versus meeting it in 2045. Data are presented with 95% uncertainty intervals.</ce:simple-para>
               </ce:legend>
            </ce:table>
         </ce:floats>
         <head>
            <ce:dochead id="cedoch10">
               <ce:textfn>Articles</ce:textfn>
            </ce:dochead>
            <ce:title id="cetitle10">Economic impact of tuberculosis mortality in 120 countries and the cost of not achieving the Sustainable Development Goals tuberculosis targets: a full-income analysis</ce:title>
            <ce:author-group id="aug10">
               <ce:author id="au10" author-id="S2214109X21002990-d2aa6f28b32a152da2d1d79ff1589cb6">
                  <ce:given-name>Sachin</ce:given-name>
                  <ce:surname>Silva</ce:surname>
                  <ce:degrees>DrPH</ce:degrees>
                  <ce:cross-ref id="cecref10" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au20" author-id="S2214109X21002990-83d6a10ea6ee9e4922ee6e20dbeeb15b">
                  <ce:given-name>Nimalan</ce:given-name>
                  <ce:surname>Arinaminpathy</ce:surname>
                  <ce:degrees>DPhil</ce:degrees>
                  <ce:cross-ref id="cecref20" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au30" author-id="S2214109X21002990-0c74971b78694f230b2ccd7c53a87a95">
                  <ce:degrees>Prof</ce:degrees>
                  <ce:given-name>Rifat</ce:given-name>
                  <ce:surname>Atun</ce:surname>
                  <ce:degrees>MBBS</ce:degrees>
                  <ce:cross-ref id="cecref30" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au40" author-id="S2214109X21002990-bc4e008b8192c1157e3037c9f7549e99">
                  <ce:degrees>Prof</ce:degrees>
                  <ce:given-name>Eric</ce:given-name>
                  <ce:surname>Goosby</ce:surname>
                  <ce:degrees>MD</ce:degrees>
                  <ce:cross-ref id="cecref40" refid="aff3">
                     <ce:sup loc="post">c</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au50" author-id="S2214109X21002990-882ea0e79317645be4d76ad4730137c5">
                  <ce:given-name>Michael</ce:given-name>
                  <ce:surname>Reid</ce:surname>
                  <ce:degrees>MD</ce:degrees>
                  <ce:cross-ref id="cecref50" refid="aff3">
                     <ce:sup loc="post">c</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="cecref60" refid="cor1">*</ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation id="aff1" affiliation-id="S2214109X21002990-7d68e3144d218783c9caaea7bef7b215">
                  <ce:label>a</ce:label>
                  <ce:textfn>Harvard T H Chan School of Public Health, Harvard University, Boston, MA, USA</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Harvard T H Chan School of Public Health</sa:organization>
                     <sa:organization>Harvard University</sa:organization>
                     <sa:city>Boston</sa:city>
                     <sa:state>MA</sa:state>
                     <sa:country>USA</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="sourcetext10">Harvard T H Chan School of Public Health, Harvard University, Boston, MA, USA</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff2" affiliation-id="S2214109X21002990-fac3d41047a70c8c5d6a6bd4100fee70">
                  <ce:label>b</ce:label>
                  <ce:textfn>Faculty of Medicine, School of Public Health, Imperial College London, London, UK</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Faculty of Medicine</sa:organization>
                     <sa:organization>School of Public Health</sa:organization>
                     <sa:organization>Imperial College London</sa:organization>
                     <sa:city>London</sa:city>
                     <sa:country>UK</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="sourcetext20">Faculty of Medicine, School of Public Health, Imperial College London, London, UK</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff3" affiliation-id="S2214109X21002990-15f388c381721599ca08d55f388a46a9">
                  <ce:label>c</ce:label>
                  <ce:textfn>Institute for Global Health Sciences and School of Medicine, University of California San Francisco, San Francisco, CA, USA</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Institute for Global Health Sciences and School of Medicine</sa:organization>
                     <sa:organization>University of California San Francisco</sa:organization>
                     <sa:city>San Francisco</sa:city>
                     <sa:state>CA</sa:state>
                     <sa:country>USA</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="sourcetext30">Institute for Global Health Sciences and School of Medicine, University of California San Francisco, San Francisco, CA, USA</ce:source-text>
               </ce:affiliation>
               <ce:correspondence id="cor1">
                  <ce:label>*</ce:label>
                  <ce:text>Correspondence to: Dr Michael Reid, School of Medicine, University of California San Francisco, San Francisco, CA 94143, USA</ce:text>
                  <sa:affiliation>
                     <sa:organization>School of Medicine</sa:organization>
                     <sa:organization>University of California San Francisco</sa:organization>
                     <sa:city>San Francisco</sa:city>
                     <sa:state>CA</sa:state>
                     <sa:postal-code>94143</sa:postal-code>
                     <sa:country>USA</sa:country>
                  </sa:affiliation>
               </ce:correspondence>
            </ce:author-group>
            <ce:abstract id="ceab10" view="all" class="author"><ce:abstract-sec id="ceabs10" view="all">
                  <ce:section-title id="cestitle20">Background</ce:section-title>
                  <ce:simple-para id="spara90" view="all">The tuberculosis targets for the UN Sustainable Development Goals (SDGs) call for a 90% reduction in tuberculosis deaths by 2030, compared with 2015, but meeting this target now seems highly improbable. To assess the economic impact of not meeting the target until 2045, we estimated full-income losses in 120 countries, including those due to excess deaths resulting from COVID-19-related disruptions to tuberculosis services, for the period 2020–50.</ce:simple-para>
               </ce:abstract-sec><ce:abstract-sec id="ceabs20" view="all">
                  <ce:section-title id="cestitle30">Methods</ce:section-title>
                  <ce:simple-para id="spara100" view="all">Annual mortality risk changes at each age in each year from 2020 to 2050 were estimated for 120 countries. This risk change was then converted to full-income risk by calculating a population-level mortality risk change and multiplying it by the value of a statistical life-year in each country and year. As a comparator, we assumed that current rates of tuberculosis continue to decline through the period of analysis. We calculated the full-income losses, and mean life expectancy losses per person, at birth and at age 35 years, under scenarios in which the SDG targets are met in 2030 and in 2045. We defined the cost of inaction as the difference in full-income losses and tuberculosis mortality between these two scenarios.</ce:simple-para>
               </ce:abstract-sec><ce:abstract-sec id="ceabs30" view="all">
                  <ce:section-title id="cestitle40">Findings</ce:section-title>
                  <ce:simple-para id="spara110" view="all">From 2020 to 2050, based on the current annual decrease in tuberculosis deaths of 2%, 31·8 million tuberculosis deaths (95% uncertainty interval 25·2 million–39·5 million) are estimated to occur, corresponding to an economic loss of US$17·5 trillion (14·9 trillion–20·4 trillion). If the SDG tuberculosis mortality target is met in 2030, 23·8 million tuberculosis deaths (18·9 million–29·5 million) and $13·1 trillion (11·2 trillion–15·3 trillion) in economic losses can be avoided. If the target is met in 2045, 18·1 million tuberculosis deaths (14·3 million–22·4 million) and $10·2 trillion (8·7 trillion–11·8 trillion) can be avoided. The cost of inaction of not meeting the SDG tuberculosis mortality target until 2045 (<ce:italic>vs</ce:italic> 2030) is, therefore, 5·7 million tuberculosis deaths (5·1 million–8·1 million) and $3·0 trillion (2·5 trillion–3·5 trillion) in economic losses. COVID-19-related disruptions add $290·3 billion (260·2 billion–570·1 billion) to this cost.</ce:simple-para>
               </ce:abstract-sec><ce:abstract-sec id="ceabs40" view="all">
                  <ce:section-title id="cestitle50">Interpretation</ce:section-title>
                  <ce:simple-para id="spara120" view="all">Failure to achieve the SDG tuberculosis mortality target by 2030 will lead to profound economic and health losses. The effects of delay will be greatest in sub-Saharan Africa. Affected countries, donor nations, and the private sector should redouble efforts to finance tuberculosis programmes and research because the economic dividend of such strategies is likely to be substantial.</ce:simple-para>
               </ce:abstract-sec><ce:abstract-sec id="ceabs50" view="all">
                  <ce:section-title id="cestitle60">Funding</ce:section-title>
                  <ce:simple-para id="spara130" view="all">None.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
         </head>
         <body view="all">
            <ce:sections>
               <ce:section id="cesec10" view="all">
                  <ce:section-title id="cestitle70">Introduction</ce:section-title>
                  <ce:para id="para10" view="all">Ending tuberculosis, a major global health threat, is widely agreed to be an attractive and important investment.<ce:cross-ref id="cecref70" refid="bib1">
                        <ce:sup loc="post">1</ce:sup>
                     </ce:cross-ref> Nonetheless, realising the UN Sustainable Development Goal (SDG) of ending the tuberculosis epidemic by 2030 now seems increasingly improbable.<ce:cross-ref id="cecref80" refid="bib2">
                        <ce:sup loc="post">2</ce:sup>
                     </ce:cross-ref> Even before the COVID-19 pandemic, there was broad scepticism that without an effective mechanism to interrupt transmission, achieving the targets would be difficult.<ce:cross-ref id="cecref90" refid="bib3">
                        <ce:sup loc="post">3</ce:sup>
                     </ce:cross-ref> Unfortunately, COVID-19 has had a profound impact on global tuberculosis programmes, interrupting routine services,<ce:cross-ref id="cecref100" refid="bib4">
                        <ce:sup loc="post">4</ce:sup>
                     </ce:cross-ref> restricting care-seeking,<ce:cross-ref id="cecref110" refid="bib5">
                        <ce:sup loc="post">5</ce:sup>
                     </ce:cross-ref> and limiting the availability of care providers and essential diagnostic products.<ce:cross-ref id="cecref120" refid="bib6">
                        <ce:sup loc="post">6</ce:sup>
                     </ce:cross-ref> Early modelling suggested that in India, Kenya, and Ukraine, a 3-month shutdown followed by a 10-month recovery period was projected to give rise to substantial additional tuberculosis burden in the next 5 years,<ce:cross-ref id="cecref130" refid="bib7">
                        <ce:sup loc="post">7</ce:sup>
                     </ce:cross-ref> adding US$1·95 billion to tuberculosis-related health spending in India, $29·43 million in Kenya, and $96·38 million in Ukraine.<ce:cross-ref id="cecref140" refid="bib8">
                        <ce:sup loc="post">8</ce:sup>
                     </ce:cross-ref> The Global Tuberculosis Report 2020 found that the 14% cumulative reduction in tuberculosis deaths from 2015 to 2019 fell far short of the 35% needed to reach the 2030 mortality target.<ce:cross-ref id="cecref150" refid="bib9">
                        <ce:sup loc="post">9</ce:sup>
                     </ce:cross-ref> Understanding the full costs and consequences of not meeting the targets is, therefore, of great importance. Moreover, a full assessment of costs strengthens the case for advanced trials and licensure of a tuberculosis vaccine, the funding for which could now be increasingly diverted towards COVID-19-related priorities. It also allows governments to carefully allocate resources that are now highly constrained.<ce:cross-ref id="cecref160" refid="bib10">
                        <ce:sup loc="post">10</ce:sup>
                     </ce:cross-ref>
                  </ce:para>
                  <ce:para id="para20" view="all">
                     <ce:display>
                        <ce:textbox id="cetextbox10">
                           <ce:caption id="cecap50">
                              <ce:simple-para id="spara140" role="caption" view="all">Research in context</ce:simple-para>
                           </ce:caption>
                           <ce:textbox-body>
                              <ce:sections>
                                 <ce:para id="para30" view="all">
                                    <ce:bold>Evidence before this study</ce:bold>
                                 </ce:para>
                                 <ce:para id="para40" view="all">We searched PubMed for articles published between Jan 1, 2000, and Dec 31, 2020, using search terms that were broadly representative of health and economic impacts of tuberculosis, inclusive of mortality and morbidity impacts, and consequent economic and welfare losses. We excluded studies that were published in languages other than English. We found that previous macroeconomic assessments of tuberculosis treatment and control have examined the impact of specific interventions such as the directly observed treatment short-course strategy, proposed in the Global Plan to Stop TB 2006–2015. Existing studies have also sought to evaluate the effect of changing tuberculosis incidence on per-capita and per-worker gross domestic product growth. The years of life lost due to tuberculosis, as well as the effects of tuberculosis treatment on all-cause mortality, have also been previously estimated, most notably as a part of benefit–cost calculations in the <ce:italic>Lancet</ce:italic> Commission on investing in health. The likelihood of meeting the tuberculosis mortality targets set in the Sustainable Development Goals (SDGs) was evaluated by the Global TB Report 2020, which concluded that the cumulative reduction in tuberculosis deaths between 2015 and 2019 was 14%, less than halfway towards the 35% reduction needed. To our knowledge, no previous estimates have been made of the effects on life expectancy or full-income due to the decline in tuberculosis deaths in 120 countries from 2020 until 2050. More importantly, there are no previous estimates of the economic consequences of meeting the SDG tuberculosis mortality target, particularly on full-income, which gives a more accurate and complete picture of the value of investments in tuberculosis control efforts compared with previous studies of economic impact.</ce:para>
                                 <ce:para id="para50" view="all">
                                    <ce:bold>Added value of this study</ce:bold>
                                 </ce:para>
                                 <ce:para id="para60" view="all">To our knowledge, this is the first study to estimate full-income losses due to tuberculosis mortality in 120 countries, in 2018, and from 2020 to 2050. Moreover, it is the first to extend these estimates to assess the economic consequences of not meeting the SDG tuberculosis mortality target by 2030. The study also establishes the contribution of tuberculosis among people living with HIV and multidrug-resistant tuberculosis to economic losses. Because our economic burden estimates are supplemented by estimates of the impact on life expectancy, they provide a complementary view of the impact of tuberculosis mortality. Lastly, the study includes estimates of the excess full-income losses due to excess tuberculosis deaths resulting from COVID-19-related disruptions in 120 countries, which, to the best of our knowledge, has not been previously estimated.</ce:para>
                                 <ce:para id="para70" view="all">
                                    <ce:bold>Implications of all the available evidence</ce:bold>
                                 </ce:para>
                                 <ce:para id="para80" view="all">This study provides an assessment of the potential impact of not meeting the SDG tuberculosis mortality target by 2030, highlighting the substantial economic losses that will result from failing to achieve a 90% reduction in tuberculosis mortality (compared with 2015) until 2045 compared with achieving it in 2030. The analysis also provides some insight into how COVID-19-related-disruptions could exacerbate these losses.</ce:para>
                              </ce:sections>
                           </ce:textbox-body>
                        </ce:textbox>
                     </ce:display>
                  </ce:para>
                  <ce:para id="para90" view="all">The economic impact of tuberculosis has been widely studied over the past 20 years.<ce:cross-refs id="cecrefs10" refid="bib11 bib12">
                        <ce:sup loc="post">11,12</ce:sup>
                     </ce:cross-refs> Tuberculosis adversely affects the labour force,<ce:cross-ref id="cecref170" refid="bib13">
                        <ce:sup loc="post">13</ce:sup>
                     </ce:cross-ref> exhausts government health budgets,<ce:cross-ref id="cecref180" refid="bib14">
                        <ce:sup loc="post">14</ce:sup>
                     </ce:cross-ref> depresses household savings,<ce:cross-refs id="cecrefs20" refid="bib15 bib16 bib17">
                        <ce:sup loc="post">15–17</ce:sup>
                     </ce:cross-refs> and disrupts local economies.<ce:cross-ref id="cecref190" refid="bib18">
                        <ce:sup loc="post">18</ce:sup>
                     </ce:cross-ref> However, the overall evidence on the economics of ending tuberculosis has remained heterogeneous, without a comprehensive assessment of the cost of the tuberculosis epidemic on economic welfare.<ce:cross-ref id="cecref200" refid="bib1">
                        <ce:sup loc="post">1</ce:sup>
                     </ce:cross-ref> The COVID-19 pandemic has reasserted the need to understand these broader welfare consequences of disease.</ce:para>
                  <ce:para id="para100" view="all">Building on the economic analysis outlined in the <ce:italic>Lancet</ce:italic> Commission on Tuberculosis,<ce:cross-ref id="cecref210" refid="bib1">
                        <ce:sup loc="post">1</ce:sup>
                     </ce:cross-ref> we provide a comprehensive assessment of the global economic impact of tuberculosis mortality. We use a full-income approach, which measures the impact on living standards in terms of consumption, and the added value of averting mortality, in terms of the individual valuation of the trade-off between consumption and health.<ce:cross-refs id="cecrefs30" refid="bib19 bib20">
                        <ce:sup loc="post">19,20</ce:sup>
                     </ce:cross-refs> We supplement the economic assessment with an assessment of the impact on population life expectancy. Correspondingly, we calculate the economic and life expectancy dividend of achieving the SDG target of reducing tuberculosis deaths by 90% of 2015 rates by 2030,<ce:cross-ref id="cecref220" refid="bib21">
                        <ce:sup loc="post">21</ce:sup>
                     </ce:cross-ref> and the respective penalties should achievement be delayed until 2045 (the best-case plausible scenario, in line with the <ce:italic>Lancet</ce:italic> Commission on tuberculosis,<ce:cross-ref id="cecref230" refid="bib1">
                        <ce:sup loc="post">1</ce:sup>
                     </ce:cross-ref> even with COVID-19). We refer to this economic and life expectancy penalty as the cost of inaction, and calculate its magnitude as well as its share attributable to HIV and multidrug-resistant (MDR) tuberculosis, across 120 countries from 2020 to 2050. We present, to the best of our knowledge, the first estimate of the global economic cost of tuberculosis mortality.</ce:para>
               </ce:section>
               <ce:section id="cesec20" view="all">
                  <ce:section-title id="cestitle80">Methods</ce:section-title>
                  <ce:section id="cesec30" view="all">
                     <ce:section-title id="cestitle90">Study design</ce:section-title>
                     <ce:para id="para110" view="all">We calculated gains in life expectancy<ce:cross-ref id="cecref240" refid="bib22">
                           <ce:sup loc="post">22</ce:sup>
                        </ce:cross-ref> from 2020 to 2050 in 120 countries (which accounted for 99·41% of global tuberculosis deaths in 2019<ce:cross-ref id="cecref250" refid="bib23">
                           <ce:sup loc="post">23</ce:sup>
                        </ce:cross-ref>), should tuberculosis deaths decline under three scenarios: at a steady 2% annually,<ce:cross-ref id="cecref260" refid="bib23">
                           <ce:sup loc="post">23</ce:sup>
                        </ce:cross-ref> referred to as the business-as-usual scenario; at a constant annual rate that allows the SDG tuberculosis mortality target to be met in 2030, and continuing on the same trajectory until 2050; or at a constant annual rate that allows the SDG tuberculosis mortality target to be met in 2045, and continuing on the same trajectory until 2050 (<ce:cross-ref id="cecref270" refid="sec1">appendix pp 14–15</ce:cross-ref>). We calculated excess deaths due to COVID-19-related disruptions in tuberculosis services on the basis of a modelling analysis by Cilloni and colleagues<ce:cross-ref id="cecref280" refid="bib7">
                           <ce:sup loc="post">7</ce:sup>
                        </ce:cross-ref> (<ce:cross-ref id="cecref290" refid="sec1">appendix p 15</ce:cross-ref>). We used the life tables and population projections for each country available from the World Population Prospects database of the UN Population Division.<ce:cross-ref id="cecref300" refid="bib24">
                           <ce:sup loc="post">24</ce:sup>
                        </ce:cross-ref>
                     </ce:para>
                  </ce:section>
                  <ce:section id="cesec40" view="all">
                     <ce:section-title id="cestitle100">Procedures</ce:section-title>
                     <ce:para id="para120" view="all">We included deaths due to tuberculosis or its sequalae (International Classification of Diseases, 10th revision codes: A15–19 and B90) and deaths in people living with HIV if tuberculosis is the contributory cause,<ce:cross-ref id="cecref310" refid="bib25">
                           <ce:sup loc="post">25</ce:sup>
                        </ce:cross-ref> all of which are estimated in the Global Tuberculosis Report 2020.<ce:cross-ref id="cecref320" refid="bib23">
                           <ce:sup loc="post">23</ce:sup>
                        </ce:cross-ref> We calculated tuberculosis deaths in each World Population Prospects life table age interval, using the age distribution of tuberculosis deaths in 2018,<ce:cross-ref id="cecref330" refid="bib26">
                           <ce:sup loc="post">26</ce:sup>
                        </ce:cross-ref> which we assumed applied through 2050 for deaths due to all causes and deaths due to all causes excluding HIV. For tuberculosis deaths in people living with HIV, we used the age incidence of HIV in 2018,<ce:cross-ref id="cecref340" refid="bib27">
                           <ce:sup loc="post">27</ce:sup>
                        </ce:cross-ref> which we assumed remained constant through 2050. To model the decline in tuberculosis deaths to meet the SDG tuberculosis mortality target in 2030 and 2045, we assumed an exponential decline at a fixed average annual rate that led to deaths in these respective years being reduced to 10% of the tuberculosis deaths in 2015.</ce:para>
                     <ce:para id="para130" view="all">We denoted the full-income losses due to tuberculosis as <ce:italic>V</ce:italic>(<ce:italic>e</ce:italic>
                        <ce:inf loc="post">0</ce:inf>, <ce:italic>e</ce:italic>
                        <ce:inf loc="post">TB</ce:inf>, <ce:italic>y</ce:italic>), where <ce:italic>e</ce:italic>
                        <ce:inf loc="post">0</ce:inf> is the hazard of mortality without tuberculosis, <ce:italic>e</ce:italic>
                        <ce:inf loc="post">TB</ce:inf> is the hazard of mortality with active tuberculosis and <ce:italic>y</ce:italic> is the income per capita. We transformed the excess hazard of mortality to standardised mortality units (∆SMU; a 1 in 10 000 change in mortality risk), then calculated the population value of this risk change for each country and year by multiplying the ∆SMU value by the population in each age interval (<ce:italic>n</ce:italic>(<ce:italic>a</ce:italic>)) and rescaling for the life expectancy at the age interval (<ce:italic>e</ce:italic>(<ce:italic>a</ce:italic>)) using life expectancy at age 35 years (<ce:italic>e</ce:italic>(35)) as the reference life expectancy. To estimate the monetary value of the risk change, we calculated the population value of the risk change at each age and then multiplied by the value of a statistical life-year (for the country and year), calculated as a proportion (γ) of the income per capita, which we modelled over the 30 years (<ce:cross-ref id="cecref350" refid="sec1">appendix p 12</ce:cross-ref>).<ce:cross-ref id="cecref360" refid="bib20">
                           <ce:sup loc="post">20</ce:sup>
                        </ce:cross-ref> For a given country and year, we thus estimated <ce:italic>V</ce:italic>(<ce:italic>e</ce:italic>
                        <ce:inf loc="post">0</ce:inf>, <ce:italic>e</ce:italic>
                        <ce:inf loc="post">TB</ce:inf>, <ce:italic>y</ce:italic>) as:</ce:para>
                     <ce:para id="para140" view="all">
                        <ce:display>
                           <ce:formula id="formula10">
                              <mml:math altimg="si1.gif">
                                 <mml:mrow>
                                    <mml:mtext>V</mml:mtext>
                                    <mml:mo stretchy="false">(</mml:mo>
                                    <mml:msub>
                                       <mml:mi>e</mml:mi>
                                       <mml:mn>0</mml:mn>
                                    </mml:msub>
                                    <mml:mo>,</mml:mo>
                                    <mml:msub>
                                       <mml:mi>e</mml:mi>
                                       <mml:mrow>
                                          <mml:mtext>TB</mml:mtext>
                                       </mml:mrow>
                                    </mml:msub>
                                    <mml:mo>,</mml:mo>
                                    <mml:mi>γ</mml:mi>
                                    <mml:mo stretchy="false">)</mml:mo>
                                    <mml:mo>=</mml:mo>
                                    <mml:mi>γ</mml:mi>
                                    <mml:mo>.</mml:mo>
                                    <mml:mi>γ</mml:mi>
                                    <mml:munderover>
                                       <mml:mo>∫</mml:mo>
                                       <mml:mn>0</mml:mn>
                                       <mml:mo>∞</mml:mo>
                                    </mml:munderover>
                                    <mml:mrow>
                                       <mml:mi>n</mml:mi>
                                       <mml:mo stretchy="false">(</mml:mo>
                                       <mml:mi>a</mml:mi>
                                       <mml:mo stretchy="false">)</mml:mo>
                                       <mml:mi>Δ</mml:mi>
                                       <mml:mtext>SMU</mml:mtext>
                                       <mml:mo stretchy="false">(</mml:mo>
                                       <mml:msub>
                                          <mml:mi>e</mml:mi>
                                          <mml:mn>0</mml:mn>
                                       </mml:msub>
                                       <mml:mo>,</mml:mo>
                                       <mml:msub>
                                          <mml:mi>e</mml:mi>
                                          <mml:mrow>
                                             <mml:mi>T</mml:mi>
                                             <mml:mi>B</mml:mi>
                                          </mml:mrow>
                                       </mml:msub>
                                       <mml:mo stretchy="false">)</mml:mo>
                                       <mml:mfrac>
                                          <mml:mrow>
                                             <mml:mi>e</mml:mi>
                                             <mml:mo stretchy="false">(</mml:mo>
                                             <mml:mi>a</mml:mi>
                                             <mml:mo stretchy="false">)</mml:mo>
                                          </mml:mrow>
                                          <mml:mrow>
                                             <mml:mi>e</mml:mi>
                                             <mml:mo stretchy="false">(</mml:mo>
                                             <mml:mn>35</mml:mn>
                                             <mml:mo stretchy="false">)</mml:mo>
                                          </mml:mrow>
                                       </mml:mfrac>
                                       <mml:mtext>da</mml:mtext>
                                    </mml:mrow>
                                 </mml:mrow>
                              </mml:math>
                           </ce:formula>
                        </ce:display>
                     </ce:para>
                     <ce:para id="para150" view="all">We calculated the value of a statistical life based on benefits transfer, by adjusting the value of a statistical life in the USA ($9 702 616) at an income of $63 280 (in purchasing power parity-adjusted international $ rates),<ce:cross-ref id="cecref370" refid="bib28">
                           <ce:sup loc="post">28</ce:sup>
                        </ce:cross-ref> assuming an income elasticity of 1·0 (1·5 considered in the sensitivity analysis).<ce:cross-ref id="cecref380" refid="bib29">
                           <ce:sup loc="post">29</ce:sup>
                        </ce:cross-ref> We calculated the present value of full-income from the perspective of 2020, assuming a discount rate of 3% (and 5% in the sensitivity analysis).<ce:cross-ref id="cecref390" refid="bib30">
                           <ce:sup loc="post">30</ce:sup>
                        </ce:cross-ref> We defined the cost of inaction as the full-income value of incremental tuberculosis deaths if the SDG tuberculosis mortality target was met in 2045 instead of 2030.</ce:para>
                     <ce:para id="para160" view="all">We did a probabilistic uncertainty and sensitivity analysis to evaluate the sensitivity to parameter uncertainty and choice. We sampled 5000 draws for parameter values, from uniform distributions (parameter boundaries are described in the <ce:cross-ref id="cecref400" refid="sec1">appendix pp 15–17</ce:cross-ref>), using a Latin hypercube sampling algorithm.<ce:cross-ref id="cecref410" refid="bib31">
                           <ce:sup loc="post">31</ce:sup>
                        </ce:cross-ref> We additionally considered sensitivity scenarios recommended for full-income-based benefit–cost analysis.<ce:cross-ref id="cecref420" refid="bib32">
                           <ce:sup loc="post">32</ce:sup>
                        </ce:cross-ref> We estimated uncertainty in all model outputs by calculating the 2·5th, 50th, and 97·5th percentiles, denoting the interval between the 2·5th and 97·5th percentile as the 95% uncertainty interval (UI).</ce:para>
                     <ce:para id="para170" view="all">All calculations, including the life table calculations and sensitivity analysis, were done using Stata (IC version 14.2) and Microsoft Excel for Mac (version 16.45). We report all costs in 2018 US$ rates using exchange rates and deflator values available from the World Bank.<ce:cross-ref id="cecref430" refid="bib33">
                           <ce:sup loc="post">33</ce:sup>
                        </ce:cross-ref>
                     </ce:para>
                  </ce:section>
                  <ce:section id="cesec50" view="all">
                     <ce:section-title id="cestitle110">Role of the funding source</ce:section-title>
                     <ce:para id="para180" view="all">There was no funding source for this study.</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="cesec60" view="all">
                  <ce:section-title id="cestitle120">Results</ce:section-title>
                  <ce:para id="para190" view="all">In 2018, the 1·4 million deaths (95% UI 1·2 million–1·7 million) due to all forms of tuberculosis in 120 countries resulted in $580·1 billion (95% UI 481·9 billion–695·2 billion) in full-income losses (an average of $407 821 per tuberculosis death). The highest losses were concentrated in sub-Saharan Africa ($200·8 billion; 141·5 billion–270·4 billion). If the deaths had not occurred or had been averted within the 2018 calendar year, then an individual living in one of the 120 countries would have gained an average of 0·47 years (SD 0·74) in life expectancy at birth, and an average of 0·27 years (0·43) in life expectancy at age 35 years. In the 33 sub-Saharan African countries, the gains would have been 1·31 years (0·95) at birth and 0·77 years (0·54) at age 35 years (<ce:cross-ref id="cecref440" refid="sec1">appendix pp 20–24</ce:cross-ref>).</ce:para>
                  <ce:para id="para200" view="all">In the 30 countries with the highest burden of MDR tuberculosis (<ce:cross-ref id="cecref450" refid="sec1">appendix pp 6–9</ce:cross-ref>), 1·2 million tuberculosis deaths (95% UI 0·9 million–1·4 million) occurred in 2018, resulting in $476·5 billion (399·7 billion–566·8 billion) in economic losses (a loss of $526 735 per tuberculosis death, on average; <ce:cross-ref id="cecref460" refid="sec1">appendix pp 20–24</ce:cross-ref>). 79·5% of the economic losses came from five countries: India, South Africa, Nigeria, Indonesia, and China, with India contributing 39·9%. The per-person gains in life expectancy at birth due to averting tuberculosis deaths were concentrated in ten countries (Mozambique, South Africa, Angola, Kenya, Democratic Republic of Congo, Nigeria, Papua New Guinea, Myanmar, India, and Indonesia), which accounted for almost 74% of gains in the 30 countries. In the 30 countries with the highest rates of tuberculosis–HIV co-infections (<ce:cross-ref id="cecref470" refid="sec1">appendix pp 6–9</ce:cross-ref>), 224 245 tuberculosis deaths occurred, resulting in an economic loss of $96·9 billion ($407 077 per tuberculosis death, on average). Of the 30 high MDR tuberculosis burden countries, ten had economic losses exceeding 5% of the 2018 gross domestic product (GDP) and of the 30 countries with the highest tuberculosis–HIV co-infection rates, 24 countries had losses exceeding 5% of the GDP (<ce:cross-ref id="cecref480" refid="sec1">appendix pp 20–24</ce:cross-ref>).</ce:para>
                  <ce:para id="para210" view="all">In the business-as-usual scenario, if tuberculosis deaths continue to decline at 2% annually until 2050, 31·8 million deaths (95% UI 25·2 million–39·5 million) could occur over the period 2020–50. The economic loss due to these deaths is $17·5 trillion (14·9 trillion–20·4 trillion) in 2020 (assuming a 3% discount rate and an income elasticity of 1·0). In 2030, the life expectancy benefit at birth of a 2% decline in global tuberculosis mortality would be 0·31 years (SD 0·49) on average and at age 35 years, it would be 0·17 years (0·26). The highest economic losses would be in south Asia ($7·1 trillion; 6·5 trillion–7·9 trillion). The greatest effect on life expectancy would be in sub-Saharan Africa, where on average a person would gain 0·84 years (0·64) in life expectancy in 2030 (<ce:cross-ref id="cecref490" refid="fig1">figure 1A</ce:cross-ref>
                     <ce:float-anchor refid="fig1"/>; <ce:cross-refs id="cecrefs40" refid="tbl1 tbl2">tables 1, 2</ce:cross-refs>
                     <ce:float-anchor refid="tbl1"/>
                     <ce:float-anchor refid="tbl2"/>).</ce:para>
                  <ce:para id="para220" view="all">By contrast, if the SDG tuberculosis mortality target were met in 2030, 8·0 million deaths (95% UI 6·3 million–10·1 million) would occur, with estimated economic losses of $4·3 trillion (3·7 trillion–5·1 trillion; <ce:cross-ref id="cecref500" refid="fig1">figure 1B</ce:cross-ref>; <ce:cross-ref id="cecref510" refid="tbl2">table 2</ce:cross-ref>). Meeting the SDG tuberculosis mortality target in 2030 would thus avert 23·8 million deaths and $13·1 trillion in economic losses, compared with the business-as-usual scenario. Averting tuberculosis deaths in people living with HIV by meeting the 2030 SDG tuberculosis mortality target (1·8 million [22·94%] of the 8·0 million deaths) would contribute $1·6 trillion to the savings of $13·1 trillion (<ce:cross-ref id="cecref520" refid="fig1">figure 1B</ce:cross-ref>; <ce:cross-ref id="cecref530" refid="sec1">appendix pp 24–29</ce:cross-ref>). Moreover, by achieving the SDG tuberculosis mortality target by 2030 instead of after 2050, in 2030, a person would gain 0·26 years (SD 0·04) in life expectancy at birth on average and 0·14 years (0·02) at age 35 years (<ce:cross-ref id="cecref540" refid="fig1">figure 1B</ce:cross-ref>, <ce:cross-refs id="cecrefs50" refid="tbl1 tbl2">tables 1, 2</ce:cross-refs>). In a country such as Lesotho, a person would gain as many as 2·00 years of life expectancy at birth in 2030; in the Central African Republic, they would gain 1·85 years (<ce:cross-ref id="cecref550" refid="tbl1">table 1</ce:cross-ref>; <ce:cross-ref id="cecref560" refid="sec1">appendix pp 24–29</ce:cross-ref>).</ce:para>
                  <ce:para id="para230" view="all">If the SDG tuberculosis mortality target were to be met in 2045, 13·7 million tuberculosis deaths (95% UI 10·8 million–17·2 million) would still occur between 2020 and 2050 (a reduction of 18·1 million tuberculosis deaths from the business-as-usual scenario; <ce:cross-ref id="cecref570" refid="fig1">figure 1C</ce:cross-ref>; <ce:cross-ref id="cecref580" refid="tbl2">table 2</ce:cross-ref>). The economic losses would be $7·3 trillion (6·2 trillion–8·6 trillion; a $10·2 trillion reduction from the business-as-usual scenario). The economic losses resulting from unaverted deaths among people living with HIV between 2020 and 2045 would be $983·4 billion (809·1 billion–1150·4 billion; <ce:cross-ref id="cecref590" refid="sec1">appendix pp 40–41</ce:cross-ref>). Moreover, meeting the SDG tuberculosis mortality target in 2045 would reduce potential gains in life expectancy by 0·16 years (SD 0·05) at birth in 2030 and by 0·09 years (0·03) at age 35 years, compared with the business-as-usual scenario (<ce:cross-ref id="cecref600" refid="fig1">figure 1C</ce:cross-ref>, <ce:cross-refs id="cecrefs60" refid="tbl1 tbl2">tables 1, 2</ce:cross-refs>). In Lesotho, life expectancy gains would be reduced by as much as 1·03 years; in Mozambique, they would be reduced by 0·73 years (<ce:cross-ref id="cecref610" refid="sec1">appendix pp 33–37</ce:cross-ref>).</ce:para>
                  <ce:para id="para240" view="all">The overall cost of inaction (ie, savings from meeting the SDG tuberculosis mortality target in 2030 that would be foregone by only meeting this target in 2045) is $3·0 trillion (95% UI 2·5 trillion–3·5 trillion; 5·7 million tuberculosis deaths [5·1 million–8·1 million]; <ce:cross-ref id="cecref620" refid="fig2">figure 2</ce:cross-ref>
                     <ce:float-anchor refid="fig2"/>; <ce:cross-ref id="cecref630" refid="tbl2">table 2</ce:cross-ref>). The cost of inaction is highest in south Asia, including or excluding people living with HIV ($1·1 trillion including people living with HIV, $1·0 trillion excluding people living with HIV). The cost of inaction for people living with HIV is highest in sub-Saharan Africa, at $427·0 billion (54·1% of the total cost of inaction), which is nearly six times that of the next highest region (east Asia and Pacific, $74·2 billion; <ce:cross-ref id="cecref640" refid="sec1">appendix pp 40–41</ce:cross-ref>). The cost of inaction in terms of life expectancy at birth across the 120 countries in 2030 is 0·10 (SD 0·01) years on average; at age 35, it is 0·05 years (0·00; <ce:cross-ref id="cecref650" refid="fig2">figure 2</ce:cross-ref>, <ce:cross-refs id="cecrefs70" refid="tbl1 tbl2">tables 1, 2</ce:cross-refs>).</ce:para>
                  <ce:para id="para250" view="all">Disruptions to tuberculosis services due to COVID-19 will increase tuberculosis deaths until 2025,<ce:cross-ref id="cecref660" refid="bib7">
                        <ce:sup loc="post">7</ce:sup>
                     </ce:cross-ref> increasing full-income losses up to 2050 by $1·0 trillion (from $17·5 trillion [95% UI 14·9 trillion–20·4 trillion] to $18·5 trillion [3·8 trillion–33·2 trillion]). If the SDG target is not met until 2045, the cost of inaction is $3·2 trillion (1·2 trillion–5·3 trillion), which represents an increase of $290·3 billion (260·2 billion–570·1 billion) compared with the cost of inaction if no disruption to tuberculosis services had been caused by COVID-19 (<ce:cross-ref id="cecref670" refid="sec1">appendix pp 41–42</ce:cross-ref>).</ce:para>
                  <ce:para id="para260" view="all">The uncertainty in tuberculosis deaths (14·4 million deaths in the business-as-usual scenario; 3·8 million deaths if the target is met in 2030; and 6·4 million deaths if the target is met in 2045) leads to a cost of inaction in the range of $2·5 trillion to $3·5 trillion. Probabilistic analysis suggests that in a high-burden country such as South Africa, when additionally considering the uncertainty due to the economic parameters (value of a statistical life and the choice of discount rate), the sensitivity to those parameters far outweighs the sensitivity to the uncertainty in tuberculosis deaths. In particular, if the income elasticity is allowed to vary between 0·5 and 1·5, full-income varies between $61·6 billion and $125·4 billion (range of $63·8 billion). The highest variation in full-income due to the uncertainty in tuberculosis deaths is $5·4 billion, due to the uncertainty in tuberculosis deaths at age 25–29 years (<ce:cross-ref id="cecref680" refid="sec1">appendix pp 46–47</ce:cross-ref>).</ce:para>
                  <ce:para id="para270" view="all">At the global level, when income elasticity is allowed to vary between 0·5 and 1·5, full-income varies between $12·3 trillion and $25·6 trillion (range of $13·3 trillion). When the US value of a statistical life in 2020 is allowed to vary between its reported lower and upper bounds ($1·8 million and $17·6 million),<ce:cross-ref id="cecref690" refid="bib28">
                        <ce:sup loc="post">28</ce:sup>
                     </ce:cross-ref> full-income varies between $15 trillion and $20·9 trillion (range of $5·9 trillion). When the discount rate is allowed to vary between 3% and 5%,<ce:cross-ref id="cecref700" refid="bib30">
                        <ce:sup loc="post">30</ce:sup>
                     </ce:cross-ref> full-income varies between $16·6 trillion and $19·4 trillion (range of $2·8 trillion; <ce:cross-ref id="cecref710" refid="sec1">appendix pp 44–45</ce:cross-ref>).</ce:para>
               </ce:section>
               <ce:section id="cesec70" view="all">
                  <ce:section-title id="cestitle130">Discussion</ce:section-title>
                  <ce:para id="para280" view="all">Failure to meet the SDG tuberculosis mortality target by 2030 will have adverse health and economic consequences. Our estimates suggest that $3·0 trillion will be lost if the target is not met until 2045, and in 2030, an average of 0·31 years at birth and 0·17 years at age 35 years will be lost per person due to tuberculosis deaths.</ce:para>
                  <ce:para id="para290" view="all">Our analysis also sheds light on the geographical distribution of these global losses. First, although aggregate economic losses are highest in the south Asia and east Asia and Pacific regions, mean life expectancy losses per person, both at birth and at age 35 years are highest in sub-Saharan Africa (6–7 times the losses in the next highest region). Welfare losses due to tuberculosis disproportionately burden sub-Saharan Africa, although the effects are less apparent due to lower per-capita incomes. Second, population age structure can protract economic welfare losses over generations. In this regard, sub-Saharan Africa is also burdened because life expectancy losses in peak productive ages can deter a much anticipated demographic dividend<ce:cross-refs id="cecrefs80" refid="bib34 bib35">
                        <ce:sup loc="post">34,35</ce:sup>
                     </ce:cross-refs> and depress income growth. Third, despite massive recent scale-up in HIV investment, loss of life expectancy in people living with HIV comprises as much as 50% to the cost of inaction. Estimates for 2018, which are least prone to uncertainty, suggest that countries that are more burdened by tuberculosis co-infections in patients with HIV accrue more life expectancy losses than countries more burdened by MDR tuberculosis. Lastly, excess tuberculosis deaths due to COVID-19-related disruptions are contained between 2020 and 2025, given the best available evidence to date.<ce:cross-ref id="cecref720" refid="bib7">
                        <ce:sup loc="post">7</ce:sup>
                     </ce:cross-ref> Although the associated excess welfare losses are also contained within this period, excess life expectancy losses can have a longer lasting effect.</ce:para>
                  <ce:para id="para300" view="all">These insights provide new evidence to guide investment in tuberculosis control. First, although full-income is a reasonable measure of broader economic welfare, it is depressed in countries with lower per-capita incomes. The share of consumption that an individual is willing to pay each year to gain an additional life-year is indeed higher when per-capita incomes are higher. Full-income also fails to capture losses due to post-tuberculosis morbidity, and the cost of mortality in individuals who received treatment and recovered.<ce:cross-ref id="cecref730" refid="bib36">
                        <ce:sup loc="post">36</ce:sup>
                     </ce:cross-ref> Life expectancy losses are a useful refinement to full-income, though not fully accounting for these deficits. Second, as much as considerations of broader welfare are important in investment decision-making, micro-level impacts on individuals and households cannot be overlooked. As two of the eight countries with the highest economic losses, 43·8% of the total tuberculosis spending in India and 51·6% in Nigeria is borne by individuals and households.<ce:cross-ref id="cecref740" refid="bib14">
                        <ce:sup loc="post">14</ce:sup>
                     </ce:cross-ref> In Indonesia, 36% of households experience catastrophic spending due to tuberculosis;<ce:cross-ref id="cecref750" refid="bib37">
                        <ce:sup loc="post">37</ce:sup>
                     </ce:cross-ref> in south India, 31% of households experience such losses.<ce:cross-ref id="cecref760" refid="bib38">
                        <ce:sup loc="post">38</ce:sup>
                     </ce:cross-ref> Third, consolidated investment in the near term will have a substantially higher impact than piecemeal investment over the longer term. Fourth, with almost 50% of economic losses in sub-Saharan Africa occurring due to the deaths of people living with HIV, investment in tuberculosis control must necessarily be separate from investment in HIV control. Lastly, although the displacement of tuberculosis funding due to COVID-19-related priorities can undoubtedly be catastrophic, with effective collaboration, smart investments, and efficient synergies, COVID-19 efforts could strengthen the global tuberculosis response and not undermine it.<ce:cross-ref id="cecref770" refid="bib8">
                        <ce:sup loc="post">8</ce:sup>
                     </ce:cross-ref>
                  </ce:para>
                  <ce:para id="para310" view="all">Among the limitations of our analysis, the most important is the uncertainty arising from projecting populations, deaths, and per-capita incomes over 30 years. Implicit in our assumption of a 2% annual decline in tuberculosis deaths in the business-as-usual scenario is the premise that the net effect of the drivers of tuberculosis mortality, and thereby tuberculosis incidence, is potentially declining. This is indeed the case with HIV in sub-Saharan Africa, where incidence has been declining at a steady 4% annually since 2017.<ce:cross-ref id="cecref780" refid="bib27">
                        <ce:sup loc="post">27</ce:sup>
                     </ce:cross-ref> However, in other high tuberculosis burden countries such as India, where the effect of HIV is marginal, declines in tuberculosis burden might be attributable to steady improvements in tuberculosis services,<ce:cross-ref id="cecref790" refid="bib39">
                        <ce:sup loc="post">39</ce:sup>
                     </ce:cross-ref> as well as gradual declines in determinants of tuberculosis, such as malnutrition.<ce:cross-ref id="cecref800" refid="bib40">
                        <ce:sup loc="post">40</ce:sup>
                     </ce:cross-ref> Our business-as-usual scenario essentially assumes that all of these existing trends would continue indefinitely. The uncertainty in projections is also elevated by the presence of COVID-19, which can alter the trajectory of tuberculosis mortality and disrupt secular and cyclical trends in economic growth. We accounted for the effects on tuberculosis mortality by predicting potential fluctuations due to COVID-19, but because COVID-19 is yet to diminish as a public health threat, the evidence is still evolving. Unfortunately, effects on economic trends are less amenable to statistical prediction given the scope of the study. The full-income estimates are also inherently sensitive to income elasticities,<ce:cross-ref id="cecref810" refid="bib41">
                        <ce:sup loc="post">41</ce:sup>
                     </ce:cross-ref> which inflate losses in higher-income settings.<ce:cross-ref id="cecref820" refid="bib42">
                        <ce:sup loc="post">42</ce:sup>
                     </ce:cross-ref> Our estimates are nonetheless consistent with empirical estimates of country values of a statistical life-year. In South Africa, we estimated a loss of US$1 249 279 per tuberculosis death. On average, each death incurs a loss of 33·76 years of life expectancy (the life expectancy at the median age in South Africa), suggesting a value of a (statistical) life-year of $37 005 per life-year. This estimate is approximately 4·4 times per-capita GDP in 2020 ($8429), which is in agreement with empirically measured values for sub-Saharan Africa (4·5 times the per-capita GDP).<ce:cross-ref id="cecref830" refid="bib43">
                        <ce:sup loc="post">43</ce:sup>
                     </ce:cross-ref> However, empirically established values of a statistical life are also now less reliable because the mean social valuation of mortality risk reduction is likely to be influenced by the emergence of the COVID-19 global pandemic. Our estimates also do not reflect losses due to deaths in individuals who received treatment for tuberculosis and then recovered.<ce:cross-ref id="cecref840" refid="bib36">
                        <ce:sup loc="post">36</ce:sup>
                     </ce:cross-ref> We also assumed that the age distribution of tuberculosis deaths for 2018 (age distribution of HIV for people living with HIV) remain unchanged until 2050, which adds further uncertainty.</ce:para>
                  <ce:para id="para320" view="all">Our analysis provides compelling evidence that the failure to act to reduce tuberculosis deaths will have major economic and demographic consequences. Although the COVID-19 pandemic has understandably diverted attention and investment in other disease control programmes, neglect of tuberculosis in particular, especially in high-burden countries, could have long-lasting economic and social effects. The current trajectory of the COVID-19 pandemic, and its effects on tuberculosis incidence, mortality, and economic losses suggest that action is needed now.</ce:para>
                  <ce:para id="para461" view="all">
                     <ce:display>
                        <ce:textbox id="cetextbox11">
                           <ce:textbox-body>
                              <ce:sections>
                                 <ce:para id="para462" view="all">
                                    <ce:bold>This online publication has been corrected. The corrected version first appeared at thelancet.com/lancetgh on September 21, 2021</ce:bold>
                                 </ce:para>
                              </ce:sections>
                           </ce:textbox-body>
                        </ce:textbox>
                     </ce:display>
                  </ce:para>
               </ce:section>
               <ce:para id="para330" role="acknowledgement" view="all">
                  <ce:bold>Contributors</ce:bold>
               </ce:para>
               <ce:para id="para340" role="acknowledgement" view="all">MR and SS conceived the study. SS developed the economic and demographic analysis. NA provided input into the technical analysis and contributed to finalising the manuscript. RA provided input into the overall analysis and contributed to finalising the manuscript. EG contributed to finalising the manuscript. MR and SS wrote the intial draft and were responsible for all subsequent revisions. All authors approved the final submitted version. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. All authors accessed and verified the data.</ce:para>
               <ce:section id="cesec80" role="data-availability" view="all">
                  <ce:section-title id="cestitle140">Data sharing</ce:section-title>
                  <ce:para id="para350" view="all">All primary data used in this study are publicly available. Our analyses are summarised in the <ce:cross-ref id="cecref850" refid="sec1">appendix (pp 20–47</ce:cross-ref>).</ce:para>
               </ce:section>
            </ce:sections>
            <ce:conflict-of-interest id="conflict-of-interest" view="all">
               <ce:section-title id="cestitle150">Declaration of interests</ce:section-title>
               <ce:para id="para360" view="all">We declare no competing interests.</ce:para>
            </ce:conflict-of-interest>
            <ce:appendices view="all">
               <ce:section id="sec1" view="extended">
                  <ce:section-title id="cestitle160">Supplementary Material</ce:section-title>
                  <ce:para id="para370" view="all">
                     <ce:display>
                        <ce:e-component id="ecomp10">
                           <ce:label>Supplementary appendix</ce:label>
                           <ce:link locator="mmc1" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/46.1" xlink:href="pii:S2214109X21002990/mmc1"/>
                        </ce:e-component>
                     </ce:display>
                  </ce:para>
               </ce:section>
            </ce:appendices>
         </body>
         <tail view="all">
            <ce:bibliography id="bibl10" view="all">
               <ce:section-title id="cestitle170">References</ce:section-title>
               <ce:bibliography-sec id="cebibsec10" view="all">
                  <ce:bib-reference id="bib1">
                     <ce:label>1</ce:label>
                     <sb:reference id="sbref10">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>MJA</ce:given-name>
                                 <ce:surname>Reid</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N</ce:given-name>
                                 <ce:surname>Arinaminpathy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A</ce:given-name>
                                 <ce:surname>Bloom</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Building a tuberculosis-free world: the <ce:italic>Lancet</ce:italic> Commission on tuberculosis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>393</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1331</sb:first-page>
                              <sb:last-page>1384</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext40">Reid MJA, Arinaminpathy N, Bloom A, et al. Building a tuberculosis-free world: the Lancet Commission on tuberculosis. Lancet 2019; 393: 1331–84.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib2">
                     <ce:label>2</ce:label>
                     <sb:reference id="sbref20">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K</ce:given-name>
                                 <ce:surname>Floyd</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P</ce:given-name>
                                 <ce:surname>Glaziou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>RMGJ</ce:given-name>
                                 <ce:surname>Houben</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T</ce:given-name>
                                 <ce:surname>Sumner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>RG</ce:given-name>
                                 <ce:surname>White</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M</ce:given-name>
                                 <ce:surname>Raviglione</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Global tuberculosis targets and milestones set for 2016–2035: definition and rationale</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int J Tuberc Lung Dis</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>723</sb:first-page>
                              <sb:last-page>730</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext50">Floyd K, Glaziou P, Houben RMGJ, Sumner T, White RG, Raviglione M. Global tuberculosis targets and milestones set for 2016–2035: definition and rationale. Int J Tuberc Lung Dis 2018; 22: 723–30.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib3">
                     <ce:label>3</ce:label>
                     <sb:reference id="sbref30">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>NA</ce:given-name>
                                 <ce:surname>Menzies</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>GB</ce:given-name>
                                 <ce:surname>Gomez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F</ce:given-name>
                                 <ce:surname>Bozzani</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet Glob Health</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>e816</sb:first-page>
                              <sb:last-page>e826</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext60">Menzies NA, Gomez GB, Bozzani F, et al. Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models. Lancet Glob Health 2016; 4: e816–26.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib4">
                     <ce:label>4</ce:label>
                     <sb:reference id="sbref40">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>AB</ce:given-name>
                                 <ce:surname>Hogan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>BL</ce:given-name>
                                 <ce:surname>Jewell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E</ce:given-name>
                                 <ce:surname>Sherrard-Smith</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet Glob Health</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>e1132</sb:first-page>
                              <sb:last-page>e1141</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext70">Hogan AB, Jewell BL, Sherrard-Smith E, et al. Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study. Lancet Glob Health 2020; 8: e1132–41.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib5">
                     <ce:label>5</ce:label>
                     <sb:reference id="sbref50">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D</ce:given-name>
                                 <ce:surname>Buonsenso</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F</ce:given-name>
                                 <ce:surname>Iodice</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J</ce:given-name>
                                 <ce:surname>Sorba Biala</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D</ce:given-name>
                                 <ce:surname>Goletti</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>COVID-19 effects on tuberculosis care in Sierra Leone</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pulmonology</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>27</sb:volume-nr>
                              </sb:series>
                              <sb:date>2021</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>67</sb:first-page>
                              <sb:last-page>69</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext80">Buonsenso D, Iodice F, Sorba Biala J, Goletti D. COVID-19 effects on tuberculosis care in Sierra Leone. Pulmonology 2021; 27: 67–69.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib6">
                     <ce:label>6</ce:label>
                     <sb:reference id="sbref60">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P</ce:given-name>
                                 <ce:surname>Venkatesan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>COVID-19 diagnostics—not at the expense of other diseases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet Microbe</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>e64</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext90">Venkatesan P. COVID-19 diagnostics—not at the expense of other diseases. Lancet Microbe 2020; 1: e64.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib7">
                     <ce:label>7</ce:label>
                     <sb:reference id="sbref70">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L</ce:given-name>
                                 <ce:surname>Cilloni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H</ce:given-name>
                                 <ce:surname>Fu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>JF</ce:given-name>
                                 <ce:surname>Vesga</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The potential impact of the COVID-19 pandemic on the tuberculosis epidemic a modelling analysis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>EClinicalMedicine</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>28</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:article-number>100603</sb:article-number>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext100">Cilloni L, Fu H, Vesga JF, et al. The potential impact of the COVID-19 pandemic on the tuberculosis epidemic a modelling analysis. EClinicalMedicine 2020; 28: 100603.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib8">
                     <ce:label>8</ce:label>
                     <sb:reference id="sbref80">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>MJA</ce:given-name>
                                 <ce:surname>Reid</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S</ce:given-name>
                                 <ce:surname>Silva</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N</ce:given-name>
                                 <ce:surname>Arinaminpathy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E</ce:given-name>
                                 <ce:surname>Goosby</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Building a tuberculosis-free world while responding to the COVID-19 pandemic</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>396</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1312</sb:first-page>
                              <sb:last-page>1313</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext110">Reid MJA, Silva S, Arinaminpathy N, Goosby E. Building a tuberculosis-free world while responding to the COVID-19 pandemic. Lancet 2020; 396: 1312–13.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib9">
                     <ce:label>9</ce:label>
                     <sb:reference id="sbref90">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:collaboration>WHO</sb:collaboration>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Global tuberculosis report 2020</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="interrefs10" xlink:href="http://www.who.int/tb/publications/global_report/en" xlink:type="simple">http://www.who.int/tb/publications/global_report/en</ce:inter-ref>
                              <sb:date>2020</sb:date>
                              <sb:date-accessed day="23" month="6" year="2021"/>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext120">WHO. Global tuberculosis report 2020. 2020. http://www.who.int/tb/publications/global_report/en (accessed June 23, 2021).</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib10">
                     <ce:label>10</ce:label>
                     <sb:reference id="sbref100">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:collaboration>Center for Global Development</sb:collaboration>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>COVID-19 and budgetary space for health in developing economies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="interrefs20" xlink:href="https://www.cgdev.org/publication/covid-19-and-budgetary-space-health-developing-economies" xlink:type="simple">https://www.cgdev.org/publication/covid-19-and-budgetary-space-health-developing-economies</ce:inter-ref>
                              <sb:date>July 16, 2020</sb:date>
                              <sb:date-accessed day="23" month="6" year="2021"/>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext130">Center for Global Development. COVID-19 and budgetary space for health in developing economies. July 16, 2020. https://www.cgdev.org/publication/covid-19-and-budgetary-space-health-developing-economies (accessed June 23, 2021).</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib11">
                     <ce:label>11</ce:label>
                     <sb:reference id="sbref110">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R</ce:given-name>
                                 <ce:surname>Laxminarayan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E</ce:given-name>
                                 <ce:surname>Klein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C</ce:given-name>
                                 <ce:surname>Dye</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K</ce:given-name>
                                 <ce:surname>Floyd</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S</ce:given-name>
                                 <ce:surname>Darley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O</ce:given-name>
                                 <ce:surname>Adeyi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Economic benefit of tuberculosis control</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="interrefs30" xlink:href="https://documents1.worldbank.org/curated/en/554871468175465282/pdf/wps4295.pdf" xlink:type="simple">https://documents1.worldbank.org/curated/en/554871468175465282/pdf/wps4295.pdf</ce:inter-ref>
                              <sb:date>2007</sb:date>
                              <sb:date-accessed day="23" month="6" year="2021"/>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext140">Laxminarayan R, Klein E, Dye C, Floyd K, Darley S, Adeyi O. Economic benefit of tuberculosis control. 2007. https://documents1.worldbank.org/curated/en/554871468175465282/pdf/wps4295.pdf (accessed June 23, 2021).</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib12">
                     <ce:label>12</ce:label>
                     <sb:reference id="sbref120">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A</ce:given-name>
                                 <ce:surname>Vassall</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Benefits and costs of TB control for the post-2015 development agenda</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:edited-book>
                              <sb:editors>
                                 <sb:editor>
                                    <ce:given-name>B</ce:given-name>
                                    <ce:surname>Lomborg</ce:surname>
                                 </sb:editor>
                              </sb:editors>
                              <sb:title>
                                 <sb:maintitle>Prioritizing development: a cost benefit analysis of the United Nations' Sustainable Development Goals</sb:maintitle>
                              </sb:title>
                              <sb:date>2018</sb:date>
                              <sb:publisher>
                                 <sb:name>Cambridge University Press</sb:name>
                                 <sb:location>Cambridge</sb:location>
                              </sb:publisher>
                           </sb:edited-book>
                           <sb:pages>
                              <sb:first-page>255</sb:first-page>
                              <sb:last-page>265</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext150">Vassall A. Benefits and costs of TB control for the post-2015 development agenda. In: Lomborg B, ed. Prioritizing development: a cost benefit analysis of the United Nations' Sustainable Development Goals. Cambridge: Cambridge University Press, 2018: 255–65.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib13">
                     <ce:label>13</ce:label>
                     <sb:reference id="sbref130">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R</ce:given-name>
                                 <ce:surname>Rajeswari</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R</ce:given-name>
                                 <ce:surname>Balasubramanian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M</ce:given-name>
                                 <ce:surname>Muniyandi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S</ce:given-name>
                                 <ce:surname>Geetharamani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X</ce:given-name>
                                 <ce:surname>Thresa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P</ce:given-name>
                                 <ce:surname>Venkatesan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Socio-economic impact of tuberculosis on patients and family in India</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int J Tuberc Lung Dis</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>869</sb:first-page>
                              <sb:last-page>877</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext160">Rajeswari R, Balasubramanian R, Muniyandi M, Geetharamani S, Thresa X, Venkatesan P. Socio-economic impact of tuberculosis on patients and family in India. Int J Tuberc Lung Dis 1999; 3: 869–77.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib14">
                     <ce:label>14</ce:label>
                     <sb:reference id="sbref140">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y</ce:given-name>
                                 <ce:surname>Su</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I</ce:given-name>
                                 <ce:surname>Garcia Baena</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>AC</ce:given-name>
                                 <ce:surname>Harle</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Tracking total spending on tuberculosis by source and function in 135 low-income and middle-income countries, 2000–17: a financial modelling study</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet Infect Dis</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>929</sb:first-page>
                              <sb:last-page>942</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext170">Su Y, Garcia Baena I, Harle AC, et al. Tracking total spending on tuberculosis by source and function in 135 low-income and middle-income countries, 2000–17: a financial modelling study. Lancet Infect Dis 2020; 20: 929–42.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib15">
                     <ce:label>15</ce:label>
                     <sb:reference id="sbref150">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H-Q</ce:given-name>
                                 <ce:surname>Pan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S</ce:given-name>
                                 <ce:surname>Bele</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y</ce:given-name>
                                 <ce:surname>Feng</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Analysis of the economic burden of diagnosis and treatment of tuberculosis patients in rural China</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int J Tuberc Lung Dis</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1575</sb:first-page>
                              <sb:last-page>1580</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext180">Pan H-Q, Bele S, Feng Y, et al. Analysis of the economic burden of diagnosis and treatment of tuberculosis patients in rural China. Int J Tuberc Lung Dis 2013; 17: 1575–80.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib16">
                     <ce:label>16</ce:label>
                     <sb:reference id="sbref160">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K</ce:given-name>
                                 <ce:surname>Lönnroth</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P</ce:given-name>
                                 <ce:surname>Glaziou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D</ce:given-name>
                                 <ce:surname>Weil</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K</ce:given-name>
                                 <ce:surname>Floyd</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M</ce:given-name>
                                 <ce:surname>Uplekar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M</ce:given-name>
                                 <ce:surname>Raviglione</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Beyond UHC: monitoring health and social protection coverage in the context of tuberculosis care and prevention</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>PLoS Med</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:article-number>e1001693</sb:article-number>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext190">Lönnroth K, Glaziou P, Weil D, Floyd K, Uplekar M, Raviglione M. Beyond UHC: monitoring health and social protection coverage in the context of tuberculosis care and prevention. PLoS Med 2014; 11: e1001693.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib17">
                     <ce:label>17</ce:label>
                     <sb:reference id="sbref170">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>BR</ce:given-name>
                                 <ce:surname>Bloom</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R</ce:given-name>
                                 <ce:surname>Atun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T</ce:given-name>
                                 <ce:surname>Cohen</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Tuberculosis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:edited-book>
                              <sb:editors>
                                 <sb:editor>
                                    <ce:given-name>KK</ce:given-name>
                                    <ce:surname>Holmes</ce:surname>
                                 </sb:editor>
                                 <sb:editor>
                                    <ce:given-name>S</ce:given-name>
                                    <ce:surname>Bertozzi</ce:surname>
                                 </sb:editor>
                                 <sb:editor>
                                    <ce:given-name>BR</ce:given-name>
                                    <ce:surname>Bloom</ce:surname>
                                 </sb:editor>
                                 <sb:editor>
                                    <ce:given-name>P</ce:given-name>
                                    <ce:surname>Jha</ce:surname>
                                 </sb:editor>
                              </sb:editors>
                              <sb:title>
                                 <sb:maintitle>Major infectious diseases</sb:maintitle>
                              </sb:title>
                              <sb:date>2017</sb:date>
                              <sb:publisher>
                                 <sb:name>The World Bank</sb:name>
                                 <sb:location>Washington, DC</sb:location>
                              </sb:publisher>
                           </sb:edited-book>
                           <sb:pages>
                              <sb:first-page>233</sb:first-page>
                              <sb:last-page>314</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext200">Bloom BR, Atun R, Cohen T, et al. Tuberculosis. In: Holmes KK, Bertozzi S, Bloom BR, Jha P, eds. Major infectious diseases. Washington, DC: The World Bank, 2017: 233–314.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib18">
                     <ce:label>18</ce:label>
                     <sb:reference id="sbref180">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D</ce:given-name>
                                 <ce:surname>Delfino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>PJ</ce:given-name>
                                 <ce:surname>Simmons</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Dynamics of tuberculosis and economic growth</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Environ Dev Econ</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>719</sb:first-page>
                              <sb:last-page>743</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext210">Delfino D, Simmons PJ. Dynamics of tuberculosis and economic growth. Environ Dev Econ 2005; 10: 719–43.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib19">
                     <ce:label>19</ce:label>
                     <sb:reference id="sbref190">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>WD</ce:given-name>
                                 <ce:surname>Nordhaus</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The health of nations: the contribution of improved health to living standards</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>SSRN</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>published online March 14.</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="interrefs40" xlink:href="https://papers.ssrn.com/abstract=302579" xlink:type="simple">https://papers.ssrn.com/abstract=302579</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                        <sb:comment>(preprint).</sb:comment>
                     </sb:reference>
                     <ce:source-text id="sourcetext220">Nordhaus WD. The health of nations: the contribution of improved health to living standards. SSRN 2002; published online March 14. https://papers.ssrn.com/abstract=302579 (preprint).</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib20">
                     <ce:label>20</ce:label>
                     <sb:reference id="sbref200">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>DT</ce:given-name>
                                 <ce:surname>Jamison</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>LH</ce:given-name>
                                 <ce:surname>Summers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G</ce:given-name>
                                 <ce:surname>Alleyne</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Global health 2035: a world converging within a generation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>382</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1898</sb:first-page>
                              <sb:last-page>1955</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext230">Jamison DT, Summers LH, Alleyne G, et al. Global health 2035: a world converging within a generation. Lancet 2013; 382: 1898–955.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib21">
                     <ce:label>21</ce:label>
                     <sb:reference id="sbref210">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M</ce:given-name>
                                 <ce:surname>Uplekar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D</ce:given-name>
                                 <ce:surname>Weil</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K</ce:given-name>
                                 <ce:surname>Lonnroth</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>WHO's new end TB strategy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>385</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1799</sb:first-page>
                              <sb:last-page>1801</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext240">Uplekar M, Weil D, Lonnroth K, et al. WHO's new end TB strategy. Lancet 2015; 385: 1799–801.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib22">
                     <ce:label>22</ce:label>
                     <sb:reference id="sbref220">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S</ce:given-name>
                                 <ce:surname>Preston</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P</ce:given-name>
                                 <ce:surname>Heuveline</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M</ce:given-name>
                                 <ce:surname>Guillot</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Demography: measuring and modeling population processes</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2000</sb:date>
                              <sb:publisher>
                                 <sb:name>Wiley-Blackwell</sb:name>
                                 <sb:location>Hoboken, NJ</sb:location>
                              </sb:publisher>
                           </sb:book>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext250">Preston S, Heuveline P, Guillot M. Demography: measuring and modeling population processes. Hoboken, NJ: Wiley-Blackwell, 2000.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib23">
                     <ce:label>23</ce:label>
                     <sb:reference id="sbref230">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:collaboration>WHO</sb:collaboration>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Global tuberculosis report 2019</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="interrefs50" xlink:href="https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-report-2019" xlink:type="simple">https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-report-2019</ce:inter-ref>
                              <sb:date>2019</sb:date>
                              <sb:date-accessed day="23" month="6" year="2021"/>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext260">WHO. Global tuberculosis report 2019. 2019. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-report-2019 (accessed June 23, 2021).</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib24">
                     <ce:label>24</ce:label>
                     <sb:reference id="sbref240">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:collaboration>UN Department of Economic and Social Affairs</sb:collaboration>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>World population prospects</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="interrefs60" xlink:href="https://esa.un.org/unpd/wpp" xlink:type="simple">https://esa.un.org/unpd/wpp</ce:inter-ref>
                              <sb:date>2019</sb:date>
                              <sb:date-accessed day="23" month="6" year="2021"/>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext270">UN Department of Economic and Social Affairs. World population prospects 2019. https://esa.un.org/unpd/wpp (accessed June 23, 2021).</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib25">
                     <ce:label>25</ce:label>
                     <sb:reference id="sbref250">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P</ce:given-name>
                                 <ce:surname>Glaziou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C</ce:given-name>
                                 <ce:surname>Sismanidis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P</ce:given-name>
                                 <ce:surname>Carel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K</ce:given-name>
                                 <ce:surname>Floyd</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Methods used by WHO to estimate the global burden of TB disease</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="interrefs70" xlink:href="https://www.who.int/tb/publications/global_report/gtbr2016_online_technical_appendix_global_disease_burden_estimation.pdf" xlink:type="simple">https://www.who.int/tb/publications/global_report/gtbr2016_online_technical_appendix_global_disease_burden_estimation.pdf</ce:inter-ref>
                              <sb:date>2016</sb:date>
                              <sb:date-accessed day="16" month="8" year="2021"/>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext280">Glaziou P, Sismanidis C, Carel P, Floyd K. Methods used by WHO to estimate the global burden of TB disease. 2016. https://www.who.int/tb/publications/global_report/gtbr2016_online_technical_appendix_global_disease_burden_estimation.pdf (accessed Aug 16, 2021).</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib26">
                     <ce:label>26</ce:label>
                     <sb:reference id="sbref260">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:collaboration>WHO</sb:collaboration>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Global tuberculosis report 2018</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="interrefs80" xlink:href="https://apps.who.int/iris/handle/10665/274453" xlink:type="simple">https://apps.who.int/iris/handle/10665/274453</ce:inter-ref>
                              <sb:date>2018</sb:date>
                              <sb:date-accessed day="23" month="6" year="2021"/>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext290">WHO. Global tuberculosis report 2018. 2018. https://apps.who.int/iris/handle/10665/274453 (accessed June 23, 2021).</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib27">
                     <ce:label>27</ce:label>
                     <sb:reference id="sbref270">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:collaboration>UNAIDS</sb:collaboration>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AIDSinfo: new HIV infections—adults (15+)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="interrefs90" xlink:href="https://aidsinfo.unaids.org?did=5f0104c9629b296603d55a9b&amp;r=world&amp;t=2020&amp;tb=m&amp;bt=mnli&amp;ts=0,0&amp;aid=5f0106a7629b296603d55aa0&amp;mav=Population:Alladults15+&amp;ml=2&amp;mt=1.html" xlink:type="simple">https://aidsinfo.unaids.org?did=5f0104c9629b296603d55a9b&amp;r=world&amp;t=2020&amp;tb=m&amp;bt=mnli&amp;ts=0,0&amp;aid=5f0106a7629b296603d55aa0&amp;mav=Population: All adults (15+)&amp;ml=2&amp;mt=1.html</ce:inter-ref>
                              <sb:date-accessed day="16" month="8" year="2021"/>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext300">UNAIDS. AIDSinfo: new HIV infections—adults (15+). https://aidsinfo.unaids.org?did=5f0104c9629b296603d55a9b&amp;r=world&amp;t=2020&amp;tb=m&amp;bt=mnli&amp;ts=0,0&amp;aid=5f0106a7629b296603d55aa0&amp;mav=Population: All adults (15+)&amp;ml=2&amp;mt=1.html (accessed Aug 16, 2021).</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib28">
                     <ce:label>28</ce:label>
                     <sb:reference id="sbref280">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:collaboration>US Environmental Protection Agency</sb:collaboration>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Guidelines for preparing economic analyses</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="interrefs100" xlink:href="https://www.epa.gov/environmental-economics/guidelines-preparing-economic-analyses" xlink:type="simple">https://www.epa.gov/environmental-economics/guidelines-preparing-economic-analyses</ce:inter-ref>
                              <sb:date>2014</sb:date>
                              <sb:date-accessed day="23" month="6" year="2021"/>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext310">US Environmental Protection Agency. Guidelines for preparing economic analyses. 2014. https://www.epa.gov/environmental-economics/guidelines-preparing-economic-analyses (accessed June 23, 2021).</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib29">
                     <ce:label>29</ce:label>
                     <sb:reference id="sbref290">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>LA</ce:given-name>
                                 <ce:surname>Robinson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>JK</ce:given-name>
                                 <ce:surname>Hammitt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>DT</ce:given-name>
                                 <ce:surname>Jamison</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>DG</ce:given-name>
                                 <ce:surname>Walker</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Conducting benefit-cost analysis in low- and middle-income countries: introduction to the special issue</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J Benefit Cost Anal</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>suppl 1</sb:issue-nr>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>14</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext320">Robinson LA, Hammitt JK, Jamison DT, Walker DG. Conducting benefit-cost analysis in low- and middle-income countries: introduction to the special issue. J Benefit Cost Anal 2019; 10 (suppl 1): 1–14.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib30">
                     <ce:label>30</ce:label>
                     <sb:reference id="sbref300">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T</ce:given-name>
                                 <ce:surname>Tan-Torres Edejer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R</ce:given-name>
                                 <ce:surname>Baltussen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T</ce:given-name>
                                 <ce:surname>Adam</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Making choices in health: WHO guide to cost-effectiveness analysis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="interrefs110" xlink:href="http://www.who.int/choice/publications/p_2003_generalised_cea.pdf" xlink:type="simple">http://www.who.int/choice/publications/p_2003_generalised_cea.pdf</ce:inter-ref>
                              <sb:date>2003</sb:date>
                              <sb:date-accessed day="16" month="8" year="2021"/>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext330">Tan-Torres Edejer T, Baltussen R, Adam T, et al. Making choices in health: WHO guide to cost-effectiveness analysis. 2003. http://www.who.int/choice/publications/p_2003_generalised_cea.pdf. (accessed Aug 16, 2021).</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib31">
                     <ce:label>31</ce:label>
                     <sb:reference id="sbref310">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>TO</ce:given-name>
                                 <ce:surname>Orwa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>RW</ce:given-name>
                                 <ce:surname>Mbogo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>LS</ce:given-name>
                                 <ce:surname>Luboobi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Uncertainty and sensitivity analysis applied to an in-host malaria model with multiple vaccine antigens</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int J Appl Comput Math</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>73</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext340">Orwa TO, Mbogo RW, Luboobi LS. Uncertainty and sensitivity analysis applied to an in-host malaria model with multiple vaccine antigens. Int J Appl Comput Math 2019; 5: 73.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib32">
                     <ce:label>32</ce:label>
                     <sb:reference id="sbref320">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>LA</ce:given-name>
                                 <ce:surname>Robinson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>JK</ce:given-name>
                                 <ce:surname>Hammitt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M</ce:given-name>
                                 <ce:surname>Cecchini</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Reference case guidelines for benefit-cost analysis in global health and development</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="interrefs120" xlink:href="https://cdn1.sph.harvard.edu/wp-content/uploads/sites/2447/2019/05/BCA-Guidelines-May-2019.pdf" xlink:type="simple">https://cdn1.sph.harvard.edu/wp-content/uploads/sites/2447/2019/05/BCA-Guidelines-May-2019.pdf</ce:inter-ref>
                              <sb:date>2019</sb:date>
                              <sb:date-accessed day="23" month="6" year="2021"/>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext350">Robinson LA, Hammitt JK, Cecchini M, et al. Reference case guidelines for benefit-cost analysis in global health and development. 2019. https://cdn1.sph.harvard.edu/wp-content/uploads/sites/2447/2019/05/BCA-Guidelines-May-2019.pdf (accessed June 23, 2021).</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib33">
                     <ce:label>33</ce:label>
                     <sb:reference id="sbref330">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:collaboration>World Bank</sb:collaboration>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>World Bank open data: official exchange rate (LCU per US$, period average)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="interrefs130" xlink:href="https://data.worldbank.org/indicator/PA.NUS.FCRF" xlink:type="simple">https://data.worldbank.org/indicator/PA.NUS.FCRF</ce:inter-ref>
                              <sb:date-accessed day="14" month="8" year="2021"/>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext360">World Bank. World Bank open data: official exchange rate (LCU per US$, period average). https://data.worldbank.org/indicator/PA.NUS.FCRF (accessed Aug 14, 2021).</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib34">
                     <ce:label>34</ce:label>
                     <sb:reference id="sbref340">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D</ce:given-name>
                                 <ce:surname>Bloom</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D</ce:given-name>
                                 <ce:surname>Canning</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J</ce:given-name>
                                 <ce:surname>Sevilla</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The demographic dividend: a new perspective on the economic consequences of population change</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2003</sb:date>
                              <sb:publisher>
                                 <sb:name>RAND Corporation</sb:name>
                                 <sb:location>Santa Monica, CA</sb:location>
                              </sb:publisher>
                           </sb:book>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext370">Bloom D, Canning D, Sevilla J. The demographic dividend: a new perspective on the economic consequences of population change. Santa Monica, CA: RAND Corporation, 2003.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib35">
                     <ce:label>35</ce:label>
                     <sb:reference id="sbref350">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>DE</ce:given-name>
                                 <ce:surname>Bloom</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M</ce:given-name>
                                 <ce:surname>Kuhn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K</ce:given-name>
                                 <ce:surname>Prettner</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Africa's prospects for enjoying a demographic dividend</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J Demogr Economics</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>83</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>63</sb:first-page>
                              <sb:last-page>76</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext380">Bloom DE, Kuhn M, Prettner K. Africa's prospects for enjoying a demographic dividend. J Demogr Economics 2017; 83: 63–76.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib36">
                     <ce:label>36</ce:label>
                     <sb:reference id="sbref360">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K</ce:given-name>
                                 <ce:surname>Romanowski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B</ce:given-name>
                                 <ce:surname>Baumann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>CA</ce:given-name>
                                 <ce:surname>Basham</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F</ce:given-name>
                                 <ce:surname>Ahmad Khan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>GJ</ce:given-name>
                                 <ce:surname>Fox</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>JC</ce:given-name>
                                 <ce:surname>Johnston</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet Infect Dis</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1129</sb:first-page>
                              <sb:last-page>1137</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext390">Romanowski K, Baumann B, Basham CA, Ahmad Khan F, Fox GJ, Johnston JC. Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2019; 19: 1129–37.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib37">
                     <ce:label>37</ce:label>
                     <sb:reference id="sbref370">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A</ce:given-name>
                                 <ce:surname>Fuady</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>TA</ce:given-name>
                                 <ce:surname>Houweling</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M</ce:given-name>
                                 <ce:surname>Mansyur</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>JH</ce:given-name>
                                 <ce:surname>Richardus</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Adaptation of the tool to estimate patient costs questionnaire into Indonesian context for tuberculosis-affected households</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Acta Med Indones</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>50</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3</sb:first-page>
                              <sb:last-page>10</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext400">Fuady A, Houweling TA, Mansyur M, Richardus JH. Adaptation of the tool to estimate patient costs questionnaire into Indonesian context for tuberculosis-affected households. Acta Med Indones 2018; 50: 3–10.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib38">
                     <ce:label>38</ce:label>
                     <sb:reference id="sbref380">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M</ce:given-name>
                                 <ce:surname>Muniyandi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>BE</ce:given-name>
                                 <ce:surname>Thomas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N</ce:given-name>
                                 <ce:surname>Karikalan</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Association of tuberculosis with household catastrophic expenditure in south India</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>JAMA Netw Open</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:article-number>e1920973</sb:article-number>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext410">Muniyandi M, Thomas BE, Karikalan N, et al. Association of tuberculosis with household catastrophic expenditure in south India. JAMA Netw Open 2020; 3: e1920973.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib39">
                     <ce:label>39</ce:label>
                     <sb:reference id="sbref390">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S</ce:given-name>
                                 <ce:surname>Mandal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>VK</ce:given-name>
                                 <ce:surname>Chadha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R</ce:given-name>
                                 <ce:surname>Laxminarayan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N</ce:given-name>
                                 <ce:surname>Arinaminpathy</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Counting the lives saved by DOTS in India: a model-based approach</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>BMC Med</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>47</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext420">Mandal S, Chadha VK, Laxminarayan R, Arinaminpathy N. Counting the lives saved by DOTS in India: a model-based approach. BMC Med 2017; 15: 47.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib40">
                     <ce:label>40</ce:label>
                     <sb:reference id="sbref400">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S</ce:given-name>
                                 <ce:surname>Swaminathan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R</ce:given-name>
                                 <ce:surname>Hemalatha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A</ce:given-name>
                                 <ce:surname>Pandey</ce:surname>
                              </sb:author>
                              <sb:et-al/>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The burden of child and maternal malnutrition and trends in its indicators in the states of India: the Global Burden of Disease Study 1990–2017</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet Child Adolesc Health</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>855</sb:first-page>
                              <sb:last-page>870</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext430">Swaminathan S, Hemalatha R, Pandey A, et al. The burden of child and maternal malnutrition and trends in its indicators in the states of India: the Global Burden of Disease Study 1990–2017. Lancet Child Adolesc Health 2019; 3: 855–70.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib41">
                     <ce:label>41</ce:label>
                     <sb:reference id="sbref410">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>JK</ce:given-name>
                                 <ce:surname>Hammitt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>LA</ce:given-name>
                                 <ce:surname>Robinson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The income elasticity of the value per statistical life: transferring estimates between high and low income populations</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J Benefit Cost Anal</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>29</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext440">Hammitt JK, Robinson LA. The income elasticity of the value per statistical life: transferring estimates between high and low income populations. J Benefit Cost Anal 2011; 2: 1–29.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib42">
                     <ce:label>42</ce:label>
                     <sb:reference id="sbref420">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M</ce:given-name>
                                 <ce:surname>Fleurbaey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S</ce:given-name>
                                 <ce:surname>Luchini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C</ce:given-name>
                                 <ce:surname>Muller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E</ce:given-name>
                                 <ce:surname>Schokkaert</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Equivalent income and fair evaluation of health care</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Health Econ</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>711</sb:first-page>
                              <sb:last-page>729</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext450">Fleurbaey M, Luchini S, Muller C, Schokkaert E. Equivalent income and fair evaluation of health care. Health Econ 2013; 22: 711–29.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib43">
                     <ce:label>43</ce:label>
                     <sb:reference id="sbref430">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>BN</ce:given-name>
                                 <ce:surname>Patenaude</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I</ce:given-name>
                                 <ce:surname>Semali</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J</ce:given-name>
                                 <ce:surname>Killewo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T</ce:given-name>
                                 <ce:surname>Bärnighausen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The value of a statistical life-year in sub-Saharan Africa: evidence from a large population-based survey in Tanzania</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Value Health Reg Issues</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>151</sb:first-page>
                              <sb:last-page>156</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sourcetext460">Patenaude BN, Semali I, Killewo J, Bärnighausen T. The value of a statistical life-year in sub-Saharan Africa: evidence from a large population-based survey in Tanzania. Value Health Reg Issues 2019; 19: 151–56.</ce:source-text>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originalText></full-text-retrieval-response>